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ABSTRACT

Side effects of radiation therapy (RT) remain the most challenging issue for
pancreatic cancer treatment. In this report we determined whether and how cerium
oxide nanoparticles (CONPs) sensitize pancreatic cancer cells to RT. CONP
pretreatment enhanced radiation-induced reactive oxygen species (ROS) production
preferentially in acidic cell-free solutions as well as acidic human pancreatic cancer
cells. In acidic environments, CONPs favor the scavenging of superoxide radical over
the hydroxyl peroxide resulting in accumulation of the latter whereas in neutral pH
CONPs scavenge both. CONP treatment prior to RT markedly potentiated the cancer
cell apoptosis both in culture and in tumors and the inhibition of the pancreatic tumor
growth without harming the normal tissues or host mice. Mechanistically, CONPs were
not able to significantly impact RT-induced DNA damage in cancer cells, thereby ruling
out sensitization through increased mitotic catastrophe. However, JNK activation, which
is known to be a key driver of RT-induced apoptosis, was significantly upregulated by
co-treatment with CONPs and RT in pancreatic cancer cells in vitro and human
pancreatic tumors in nude mice in vivo compared to CONPs or RT treatment alone.
Further, CONP-driven increase in RT-induced JNK activation was associated with
marked increases in Caspase 3/7 activation, indicative of apoptosis. We have shown
CONPs increase ROS production in cancer cells; ROS has been shown to drive the
oxidation of thioredoxin (TRX) 1 which results in the activation of Apoptosis Signaling
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Kinase (ASK) 1. The dramatic increase in ASK1 activation following the co-treatment of
pancreatic cancer cells with CONPs followed by RT in vitro suggests that increased the
c-Jun terminal kinase (JNK) activation is the result of increased TRX1 oxidation. The
ability of CONPs to sensitize pancreatic cancer cells to RT was mitigated when the
TRX1 oxidation was prevented by mutagenesis of a cysteine residue, or the JNK
activation was blocked by an inhibitor,. Additionally, angiogenesis in pancreatic tumors
treated with CONPs and RT was significantly reduced compared to other treatment
options. Taken together, these data demonstrate an important role and mechanisms for
CONPs in specifically killing cancer cells and provide novel insight into the utilization of
CONPs as a radiosensitizer and therapeutic agent for pancreatic cancer.
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This work is dedicated to the memory of my grandfather
who was lost to pancreatic cancer.

Raymond McCarthy
March 18, 1930 – January 10, 1989
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CHAPTER 1: GENERAL INTRODUCTION
Cancer
Cancer, which remains one of the leading causes of death, is responsible for
causing one out of every four deaths in the United States each year (1). Over the last 40
years, medical and technological advances have allowed for improvements in early
diagnosis and the subsequent treatment of patients. As a result, the 5-year survival rate
for most cancers has markedly increased in the last few decades (1). Regardless, in
2012 alone, over 1.6 million new cases of cancer were expected and over 500,000 lives
were lost to the disease (1). Therefore, development of new and more effective
therapies remains essential and challenging.
Pancreatic Cancer
While the prognosis for other disease sites, such as breast and colon, has
significantly improved in recent years, pancreatic cancer patients still face a dismal
outlook (2); pancreatic cancer survival has not shown much improvement over the last
30 years (1). Pancreatic cancer, while representing only 6% of the new cancer
diagnoses in the United States, is projected to cause 13% of all cancer related deaths
and claimed nearly 40,000 lives in 2012 alone (1). Pancreatic cancer remains one of the
few cancers where the number of new diagnoses each year and number of annual
projected deaths from the disease are nearly identical (1), illustrating the devastating
nature of the disease, as well as the inadequacy of the current treatment options after
diagnosis.
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Pancreatic cancer is characterized by several symptoms, often as common as
abdominal pain, back pain, or the development of diabetes (3). Other symptoms, such
as painless jaundice or the pain associated with the compression of the coeliac and
mesenteric nerves, are more readily associated with pancreatic cancer and generally
result in a quick diagnosis (3). Tissue biopsy to confirm the diagnosis is usually obtained
after the identification of a pancreatic mass (3). Once the cancer is officially diagnosed,
treatment options are assessed.
Current Treatment Options
Cancer treatment can have multiple goals. In patients diagnosed with the early
stages of the disease, doctors strive to cure the disease. In patients with advanced, late
stage cancers, the treatments are often palliative, intended to extend the life of a patient
and increase comfort, rather than actually remedy the disease (4). However, a common
goal between the two types of treatment is the maintenance of quality of life for patients,
both during treatment and potentially after treatment (4). It is estimated that pain is a
symptom of up to 70% of cancers, with pain stemming from primary tumor growth and
metastasis (5). Additionally, patients often face adverse side effects from treatment,
including pain, nausea, fatigue, hair loss, and skin irritation. Managing these factors has
become increasingly important as the intensity of treatment has increased over the last
few decades.
Pancreatic cancer is one disease that is particularly difficult to treat, as
pancreatic cancers are often resistant to many of the currently available treatments (3).
2

Over 75% of pancreatic cancer patients present with inoperable disease as a result of
the fact that pancreatic cancer generally disseminates to distant sites early in the
disease progression (3). The primary tumor is not usually the killer in pancreatic cancer
patients; nearly all pancreatic cancer patients develop metastases and die of the
devastating effects of uncontrolled metastatic growth (3). Despite the number of
advances in cancer treatment and the vast array of available drugs, treatments are still
generally separated into three main categories: surgery, chemotherapy, and radiation
therapy.
Surgery
Surgical resection remains the gold standard for cancer treatment. However,
successful resection does not correlate with increased survival in pancreatic cancer
patients (3). Most pancreatic cancer patients that undergo surgical resection die from
recurrence of the disease in distant metastatic sites, indicating that surgery alone is an
inadequate treatment for pancreatic cancer (2). Preoperative and postoperative
chemoradiation has been added to the treatment plan for many patients, with some
success (3).
Chemotherapy
Chemotherapy treats cancer by attempting to kill cancer cells with cytotoxic
drugs. Currently, pancreatic cancer patients receive treatment including fluorouracil,
cisplatin, or paclitaxel, with gemcitabine being the standard for metastatic pancreatic
cancer (3). However, selectivity of chemotherapy agents remains a significant problem
3

with nearly 50% of patients requiring hospitalization with this approach due to extreme
drug toxicity (3). Chemotherapeutic agents kill cancer in a number of ways, from binding
and crosslinking DNA to pyrimidine analogues which get incorporated into DNA and
induce cell cycle arrest. Reports indicate that current chemotherapy options will not cure
metastatic pancreatic cancer (3) which, as discussed, characterizes the majority of
patients at the time of diagnosis. Therefore, the potential benefits of chemotherapy must
be dutifully considered against the toxic side effects. New, more effective chemotherapy
agents could have a substantial impact on pancreatic cancer treatment.
Ionizing Radiation Therapy
Ionizing radiation therapy (RT) is a commonly used tool to treat various types of
cancer, with more than half of all cancer patients receiving RT at some point during
treatment (6). RT kills cells by transferring energy to cellular components to break down
chemical bonds resulting in DNA damage, protein damage, and the generation of
reactive oxygen species (ROS) (6). RT has shown distinct survival benefits in most
cases (6) and, although not yet thoroughly investigated, studies have suggested that RT
decreased the pain associated with advanced pancreatic cancer in more than 50% of
patients receiving the treatment (3).
However, radiation has also been associated with negative effects for cancer
patients; pain and nausea are often associated with the treatment. Radioprotectants,
compounds designed to protect normal tissues from the harmful side effects of RT
thereby increasing the therapeutic window, have shown some benefits. Yet, Amifostine
4

continues to be the only radioprotective agent actively used in clinics (7). Amifostine is
itself associated with toxic side effects and requires repeated dosing. There is a clear
need for new radiation adjuvants.
Conflicting opinions exist about the long term effects of RT, with several reports
indicating that the population of cells which survive RT develops a more aggressive
phenotype characterized by survival, invasion, and metastasis (6). Additionally,
radiation has been shown to promote survival by driving angiogenesis in tumors (6).
Other non-targeted responses to RT have also become a concern, as RT has been
shown to activate pathways not associated with DNA damage. However, the
identification and characterization of the non-targeted responses could provide novel
targets to improve RT for patients.
Combination Therapy: Chemoradiation
The combination of chemotherapy and radiation therapy, commonly referred to
as “chemoradiation,” is the standard treatment for locally advanced and inoperable
pancreatic cancer (3). Research suggests that the combination of radiation therapy with
chemotherapy agents enhances the efficacy of treatment (6). Chemoradiation offers
significant survival, in some cases as much as doubling the resulting survival time when
a chemotherapy agent is added to existing radiation treatment options (3).
Chemoradiation is also associated with palliative benefits, thereby improving the quality
of life of many pancreatic cancer patients (3).
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One of the main goals for combing RT and chemotherapy is to sensitize cancer
cells to the toxic effects of treatment (radiosensitization). Radiosensitizers act through
numerous mechanisms. Suberoylanilide hydroxamic acid (SAHA), which is a histone
deacetylse inhibitor, relaxes the DNA structure and increase expose to RT (8). Other
chemotherapy agents, such as Gemcitabine, have also been associated with
sensitization of pancreatic cancer cells to RT (3). The approach of combining
chemotherapeutics and radiation has shown promise in the treatment of many cancers.
However, current chemoradiation options rarely control advanced pancreatic cancers
for extended periods of time, with tumor progression and metastasis occurring in most
patients within several months of the completion of treatment (3). Therefore, there is a
desperate need for novel therapies and adjuvants in the treatment of pancreatic cancer
to improve and extend the lives of patients.
Nanoparticle Based Cancer Therapies
In recent years, nanotechnology has become a main focus of biomedical
research; nanoparticles applications include drug delivery systems, luminescent
biomarkers, and tissue engineering, among others (9). Nanomedicine, as the
application of nanoparticles to medicine is commonly referred, aims to overhaul the
current treatment of diseases with more effective therapies (10). Nanoparticle
encapsulation has been shown regulated tissue and cellular distribution of many drugs
(11).

Tumors

also

possess

abnormal

physiological

pathologies,

such

as

hypervascularization, that result in unique interactions with nanoparticles (11).
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Therefore, converting current cytotoxic agents into nanoparticle based therapies is of
particular interest in the context of cancer for the potential to increase tumor growth
inhibition and cell death, yet reduce systemic side effects (11).
Beyond the common cytotoxic agents, several inorganic nanoparticles have
shown biocompatibility and are currently being investigated in the context of cancer
treatment. Superparamagnetic iron oxide nanoparticles (SPIONs) and titanium oxide
(TiO2) nanoparticles have shown promise in testing as magnetic resonance imaging
(MRI) contrast agents to detect tumors (10). Research indicates gold nanoparticles
possess inherent anti-tumor and anti-angiogenic properties (10). Additionally, gold
nanoparticles have been developed as targeted drug delivery systems in cancers
overexpressing epidermal growth factor receptors (EGFR) or folate receptors (FR) (12).
The class of inorganic nanoparticles and the applications for cancer are rapidly being
explored with largely positive results.
Cerium Oxide Nanoparticles
In particular, cerium oxide nanoparticles (CONPs), which consist of a cerium (Ce)
core surrounded by an oxygen (O) lattice, have shown promise in a number of cancer
related applications. Initial interest in CONPs stemmed from the ability of surface
oxygen vacancies to interact with and potentially modulate free radicals. CONPs have
since been shown to display a number of antioxidant behaviors, including superoxide
dismutase (SOD) activity (13), catalase mimetic activity (14), nitric oxide radical
scavenging (15), and hydroxyl radical scavenging (16).
7

However, environmental

conditions appear to play an important role in the determination of activity, as CONPs
also possess direct oxidant behavior (17). To date, pH is one of the few factors shown
to drive whether CONPs act as oxidants or antioxidants (18,19). Surely, there are other,
yet unidentified, factors that will also play a role in determining the manifestation of
radical modulation by CONPs.
Uptake and Localization
CONPs have been shown to enter mammalian cells in both normal and diseased
states (20-22), with significant uptake occurring within 3 hours of exposure in culture
(23). CONPs appear to take multiple routes into cells. Uptake has been suggested to
occur via receptor-mediated endocytosis in both lung cancer and normal lung cell lines
(24). Other studies have shown CONP uptake via clathrin-mediated and calveolaemediated endocytitic pathways (23). Particle size and surface charge have been shown
to influence cellular uptake of CONPs, but the impact of factors such as pH and cell
type has yet to be fully elucidated in the context of CONP uptake.
There is also some debate about the fate of CONPS once inside the cell. Some
studies show CONPs accumulate in the cytoplasm without translocation to the nucleus
(20,21). Other studies have demonstrated CONPs accumulate primarily in the perinuclear space (25), while still others detected CONPs co-localized with the
mitochondria, endoplasmic reticulum, lysosomes, as well as diffuse throughout the
cytoplasm and nucleus (23). Particle size and surface charge also appear to be
determinants of CONP cellular localization (18). As the differential pH of various sub8

cellular localizations has been shown to be a determinant CONPs’ anti- or pro-oxidant
activity (18), discovering where CONPs predominantly reside in the cell or why they
localize to different sub-cellular locations in different cell types may provide further
insight into their function. Manipulation of CONPs to target specific cells or sub-cellular
locations is a path that has yet to be fully elucidated and exploited.
Biodistribution and Biopersistence
Several reports have shown CONPs (<10 nm) to be well tolerated by animals
without inducting overt toxicity or an immune response across a range of doses (26-28).
When administered intravenously (IV) or intraperitoneally (IP), studies show that
CONPs accumulate primarily in the spleen and liver, to a lesser extent in the lungs and
kidneys, but not in the heart or brain (26,29). Tissues such as the breast and pancreas
have not been analyzed for retention, yet nearly half of the injected CONPs remained in
undetermined locations within the body (29). Further, CONPs were not readily cleared,
persisting in the animals at least 30 days without any appreciable CONP concentration
in the urine or feces (26,29), suggesting that other CONP destinations within the body
have yet to be identified.
Toxicity
Despite the apparent lack of toxicity in animal models, reports provide conflicting
data about the toxicity of CONPs in vitro, likely attributable to the impact of
undetermined cellular and environmental factors on the manifestation of anti- or prooxidant behavior. CONPs are toxic to bronchial epithelial lung fibroblasts in culture (25),
9

but non-toxic to mammary epithelial cells (30), macrophages (31), or immortalized
keratinocytes (23). In normal cells to which they are not toxic, the physiological pH is an
environment which enables canonical radical scavenging by CONPs. Therefore,
CONPs introduced prior to ROS insult confer protection from the effects of oxidative
stress in vitro and in vivo (32-35).
However, published data indicates that CONPs are toxic to several types of
human cancer cells in vitro, including squamous cell carcinoma (20) and alveolar
epithelial cancer cells (36). Cellular toxicity is attributed to the generation of

ROS

(19,20) and the induction of oxidative stress (36), at least in part by the inherent oxidase
activity of the nanoparticle core at acidic pH similar to that of cancer cells (17). In
particular, CONP treatment has been shown to induce glutathione oxidation, lipid
peroxidation, and membrane damage in lung cancer cells (36). Further experiments
have demonstrated that generation of CONPs with a negative surface charge can
induce preferential accumulation in acidic lysosomes within the cell, resulting in
increased toxicity selectively in cancer cells (18).
Cancer Treatment
Anti-invasive Properties:
In addition to CONPs’ toxicity to cancer cells in vitro and in vivo, studies have
shown polymer-coated CONPs to also manipulate tumor-stroma interactions to the
detriment of tumor progression and invasion (20). Polymer coating of CONPs increases
aqueous solubility (18), yet does not appear to impact CONP redox activities (17,20).
10

Epithelial-stromal signaling is largely mediated by myofibroblasts, which play a key role
in the expression of extracellular matrix components, including α-smooth muscle actin
and collagen, to facilitate tumor invasion and angiogenesis (37). With the transition from
fibroblast to myofirbroblast driven by transforming growth factor beta 1 (TGFβ1) induced ROS-dependent expression of α-smooth muscle actin, data shows CONPs
possess the ability to modulate myofibroblast formation (20). Pre-treatment with CONPs
mitigated both TGFβ1-induced α-smooth muscle actin expression in fibroblasts and the
corresponding myofibroblast transition (20). As some myofibroblasts localize to the
invasion front of tumors, CONP treatment diminished the ability of myofibroblasts to
induce invasion by squamous tumor cells in vitro (20). Interestingly, CONPs were also
able to decrease the intrinsic ability of cultured squamous tumor cells to invade, even in
the absence of any myofibroblast stimulation (20). Taken together, these data
demonstrate the direct negative effects of CONPs on cancer cells, as well as their ability
to modulate the tumor environment and indirectly inhibit tumor cell invasion.
Radioprotection
The ability of CONPs to modulate ROS has led to their exploration for the
improvement of current cancer treatments, mainly radiation therapy (RT). As discussed,
in addition to surgery and chemotherapy, RT remains a mainstay in the treatment of
cancer, with nearly half of all cancer patients receiving RT at some point during
treatment (38). Despite the many harmful side effects are associated with the RT,
including fatigue, nausea, and dermatitis, few radiation adjuvants are available to
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mitigate these painful outcomes. For example, Amifostine, which remains the only
clinically available radio-protectant (38), is itself associated with nausea and
hypotension (39). The dual capabilities of CONPs to act as an antioxidant in normal
cells, yet oxidant in cancer cells, supports the role of CONPs as an adjuvant for RT that
could significantly impact patient quality of life.
In line with the protection from other methods of inducing oxidative stress,
several publications have shown that treatment with CONPs prior to RT exposure
decreases the RT-induced cell damage and death in normal tissues of the
gastrointestinal tract (28), lung (27), breast (30), and head and neck (7).
Mechanistically, CONP radical scavenging inhibited the resulting caspase 3 activation in
irradiated colonic crypt tissue (28), as well as capsase 3 and 7 activation in irradiated
lung fibroblasts in culture (27). CONPs also increased super oxide dismutase 2 (SOD2)
expression up to two-fold in a dose dependent manner in normal human colon cells in
vitro, while increasing SOD2 expression by 40% in colonic crypt cells from mice treated
with CONPs (28). Together, these data indicate that CONPs protect normal cells both
directly, by scavenging cellular ROS, and indirectly, by priming cells to respond to ROS
insult.
Radiosensitization
Conversely, in cancer cells with acidic pH, pre-treatment with CONPs has been
predicted (18) to enhance the ability of RT to induce cell death. As acidic pH has been
shown to inhibit the catalase activity of CONPs (20), it is suggested that CONPs in
12

cancer cells are only capable of catalyzing the conversion of highly unstable superoxide
to far more stable H2O2. Without the ability to act as a catalase mimetic and remove
H2O2, CONPs could enhance the toxicity of RT in cancer cells by encouraging the
accumulation of stable ROS in the cell, which has been shown to induce cell death.
Overall, it is suggested that CONPs modulate ROS in cancer cells such that, not only
are there direct toxic effects, but the therapeutic properties of CONPs extend to radiosensitization of cancer cells and potentially sensitization to other ROS-inducing
therapies.
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CHAPTER 2: SENSITIZATION OF PANCREATIC CANCER CELLS TO RADIATIAON
BY CERIUM OXIDE NANOPARTICLE-INDUCED ROS PRODUCTION
Introduction
Pancreatic cancer carries an extremely poor prognosis, with 90% of pancreatic
cancers being malignant and the 5-year survival rate after diagnosis hovering at 5%
(40). Less than 20% of patients are candidates for surgical resection (40); therefore,
chemotherapy and radiation therapy (RT) remain the only other treatment options.
Ionizing radiation used in RT induces the radiolysis of water which generates reactive
oxygen species (ROS), such as superoxide and hydroxyl radicals. These molecules
play an important role in the subsequent cellular events such as DNA damage
potentially leading to apoptosis. Unfortunately, RT induces side effects, including skin
irritation, loss of appetite, fatigue, and nausea, as well as the pain associated with these
conditions.
Research to reduce the unwanted side effects of RT has yielded two categories
of compounds: radiation protectants and radiation sensitizers. Radiation protectants
selectively protect normal tissue from the harmful impact of ionizing radiation, while
radiation sensitizers, such as histone deacetylase (HDAC) inhibitors, selectively
increase the damage ionizing radiation induces in cancer cells. Side effects associated
with currently available protectants such as Amifostine include nausea, vomiting, and
hypotension (39), as well as high costs, increasing the cost of the overall treatment (41).
Suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor currently in the late stage
clinical trials as a radiation sensitizer, has been associated with fatigue, dehydration,
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nausea, and vomiting (42). Therefore, creation and identification of novel compounds
that improve the efficacy and therapeutic index of RT would directly improve cancer
treatment. Yet, as evidenced by the disparity between for the number of patients
receiving RT and how few radiation protection/sensitization compounds exist, identifying
viable adjuvants has proved elusive.
Nanoparticle based therapies for cancer treatment is a rapidly growing field, with
recent publications highlighting the ability of Ag microspheres (43) and folic acidconjugated silica-modified gold nanorods (44) to act as radiosensitizers. Cerium oxide
nanoparticles (CONPs) have been used as an adjuvant to improve RT in pre-clinical
trials. Wide range CONP applications stem from the surface chemistry of the
nanoparticles. The valence state and oxygen defects allow CONPs to act as autoregenerative redox status modulators (45). Recently, CONPs have been shown to be
capable of entering mammalian cells (46) and have implications in biological systems.
The antioxidant behavior of CONPs has been employed to treat diseases of the
central nervous system (47), repair spinal cord injuries (47), and extend the life of
neurons in vitro (48). The antioxidant properties of CONPs allow them to decrease the
accumulation of ROS and prevent subsequent ROS-induced apoptosis in normal cells
(34). Biochemically, CONPs have been shown to act as either a superoxide dismutase
(SOD) mimetic (49), converting superoxide to hydrogen peroxide (H2O2), or a catalase
mimetic (14), converting H2O2 to water. It is through these mechanisms that previous
work suggests CONPs are able to protect normal tissue from radiation-induced damage
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in the lungs (27), breast (30), and gastrointestinal tract (28). Most recently, CONPs were
shown to scavenge hydroxyl radicals (16) and possess intrinsic oxidase activity (17), as
well as cytotoxic and anti-invasive properties in melanoma cells (20,24,25,36). Due to
the array of radical interactions (both pro- and antioxidant) now established, CONPs can
no longer be strictly characterized as free radical scavengers and must be viewed as
free radical modulators.
This study examines the ability of CONPs to drive ROS accumulation, as well as
the subsequent impact on pancreatic cancer cell survival in vitro and in vivo. Our data
demonstrate that the pro-oxidant activity of CONPs drives radiation-induced radical
production selectively in pancreatic cancer cells resulting in radiation sensitization to
apoptotic death and growth inhibition. These results identify CONPs as a potentially
novel radiation sensitizer for the treatment of human pancreatic cancer.

Methods and Materials
Cell Culture and Reagents
The normal pancreatic cells (hTERT-HPNE) were obtained from American Type
Culture Collection (ATCC) and maintained in 3:1 glucose free DMEM:M3 Base medium,
supplemented with 10% fetal bovine serum and 100 µg/mL gentamycin. The human
pancreatic cancer cell line L3.6pl (50) was cultured in DMEM, supplemented with 10%
fetal bovine serum and 100 µg/mL penicillin-streptomycin mixture (GIBCO) and
maintained at 37oC and 5% CO2. CONPs were purchased from NanoScale Corporation
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(Manhattan, KS) or synthesized as previously described (51).

Hydrogen peroxide

(H2O2) was purchased from Sigma Aldrich (St. Louis, MO).

Transmission Electron Microscopy of CONPs
The sizes and shapes of the nanoparticles were determined by high-resolution
transmission electron microscopy (TEM) as previously described (52,53).

ROS Imaging
L3.6pl and hTERT-HPNE cells were plated in 6-well plates (5 x 104/well) and 24
hours later treated with 10 µM CONPs in fresh media for 24 hours. Subsequently, cells
were exposed to 5 Gy RT using a 160-kV cell culture and small animal irradiator
(Kimtron Inc., Woodbury, Connecticut). ROS production was determined 0.5 and 24
hours post RT by Image-iT LIVE Green ROS Detection Kit (Invitrogen) according to
manufacturer’s protocol. The kit provides carboxy-H2DCFDA. The carboxy-H2DCFDA
permeates live cells and is cleaved by cellular esterases into carboxy-DCFH. In the
presence of cellular ROS, the carboxy-DCFH is then oxidized to produce carboxy-DCF,
resulting in the emission of a bright green fluorescence.

Alternatively, cells were

cultured in 6 well plates for 24 hours followed by exposure to RT. 24 hours post RT, the
media was replaced with fresh media containing CONPs (10 µM). ROS production was
determined 3 and 24 hours post addition of CONPs. Photographs are representative
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images from triplicate experiments, which were quantified using NIH ImageJ software to
determine the number of fluorescent cells per field of view.

Cell Viability Assays
L3.6pl or hTERT-HPNE cells were plated (2 x 103/well) and grown in 96-well
plates for 24 hours and then treated with CONPs (10 µM) for an additional 24 hours,
followed by exposure to 5 Gy RT. Cell viability was determined 96 hours post RT by the
Cell Titer-Glo Luminescent Cell Viability Assay from Promega (Madison, Wisconsin) and
an Optima Fluor Star Luminometer (BMG Lab Tech, Durham, NC) following the
manufacturers’ protocols.

Clonogenic Assays
L3.6pl cells were plated (1 x 106/10-cm dish), grown for 24 hours and then
treated with CONPs (10 µM) for an additional 24 hours. Immediately after exposed to 5
Gy RT, the cells were trypsinized and re-seeded (100 cells/well) into 6 well dishes. One
week later, cells were stained with 6.0% gluteraldehyde (vol/vol), 0.5% crystal violet
(wt/vol) in water and photographed colonies of greater than 50 cells were counted (54).

Hydrogen Peroxide Assays
H2O2 production by ionizing radiation (0-30 Gy), CONPs (0-200 µM) or the
combinations of both was determined in 50 µL of water or phosphate-buffered saline
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(PBS) at various pH values (pH 7.4, pH 5, and pH 3) by Amplex Red Assay (Invitrogen)
following the manufacturer’s protocol. The combination treatments include two
strategies: 1) irradiating 50 µL of CONP suspension and determining the time-course (025 h) of H2O2 production, and 2) irradiating 48 µL of water or PBS first, waiting for 1 or
24 hours and then adding 2 µL of CONP prior to determining the H2O2 production at a
desired time point.

Intracellular Acidity Assay
L3.6pl or hTERT-HPNE cells were seeded at 500,000 cells per 6-cm dish and
grown overnight. The medium was then removed and cells were incubated in 500 µL
HBSS containing 1 µM BCECF-AM (Invitrogen) for 45 minutes.

Cells were then

trypsinized, washed twice with fresh media, and re-suspended in 1 mL HBSS. Flow
cytometry was used to determine cellular fluorescence (as defined by the ratio of
FITC/APC). Decreased fluorescence indicates increased intracellular acidity.

Superoxide Radical and Hydrogen Peroxide Scavenging Analysis
SOD mimetic activity of CONPs with different surface valance state to scavenge
superoxide radical at neutral (pH 7) and acidic pH (pH 3) was determined using a SOD
assay kit (Sigma-Aldrich, Kit #19160-1KTF) according to the manufacturer’s instructions
(55). Catalase mimetic activity of CONPs to scavenge hydrogen peroxide under the
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same conditions was determined using an Amplex Red hydrogen peroxide assay kit
(Life Technology, Cat # A22188) according to the manufacturer’s instruction.

Orthotopic Injection of Pancreatic Cancer Cells in Athymic Nude Mice
Female athymic nude mice (NCI-nu) were purchased from the Animal Production
Area of the National Cancer Institute Frederick Cancer Research and Development
Center. The mice were housed and maintained in specific pathogen-free conditions in
facilities approved by the American Association for Accreditation of Laboratory Animal
Care and in accordance with current regulations and standards of the United States
Department of Agriculture, United States Department of Health and Human Services,
and the National Institute of Health. The mice of 8 to 12 weeks of age were used in
accordance under institutional guidelines with approved IACUC protocol. Human care of
the mice was thoroughly considered. To develop tumors, L3.6pl cells were harvested
from culture dishes and injected as previously described (56-58).

Therapy of Established Human Pancreatic Carcinoma Tumors Grown in the Pancreas
of Nude Mice
Immediately following injection of cancer cells (1 x 10 6) into the pancreas, the
mice were randomized into two groups (n = 20) as follows: (a) twice weekly
intraperitoneal (i.p.) injections of saline in control groups; (b) twice weekly (Tuesday and
Thursday) i.p injections of CONPs (15 µM; 0.01 mg/kg). Two weeks later each group
was randomized into 2 sub-groups (n = 10) as follows: (c) continued with twice weekly
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i.p injections of saline (for control group) or twice weekly i.p. injections of CONPs; (d)
twice weekly i.p. injections of saline or CONPs and thrice-weekly administration of 5 Gy
radiation for 2 weeks (30 Gy total). All treatment groups continued to receive twice
weekly i.p. injections of saline (control) or CONPs for 2 additional weeks (for a total of 6
week treatment). Mice were sacrificed at 8 weeks (day 56) and subjected to necropsy.
Primary tumors in the pancreas were excised and weighed. Tumor volumes were
determined by liquid displacement analysis.

Histologic Analysis of Tumors
For hematoxylin and eosin (H & E) staining, tissues were fixed in formalin,
embedded in paraffin, and serially sectioned at 200 µm. H & E staining was performed
based on standard protocol. Paraffin-embedded tissues were used for TUNEL staining.
TUNEL-positive cells were detected using the DeadEnd Colorimetric TUNEL System
(Promega, Madison, WI). Immunohistological microscopy was performed using 10x and
40x objectives on a Nikon E400 microscope (Nikon Instruments, Melville, NY). Routine
procedures were used to capture images. Immunopositive cells for TUNEL staining
were observed over 10 individual slides for each condition and quantified using the NIH
ImageJ software to determine the number of TUNEL positive cells per field of view.
Independent review by the Pathology Department at Orlando Health/MD Anderson
Cancer Center Orlando confirmed the results.
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Statistical Analysis
All the experiments were completed in three triplicates and the data are
presented as mean ± standard deviation (SD). The data presented in Table 1 are
presented as mean and range. Statistical analysis was performed using Student's t-test,
and P value was calculated based on two-tailed test. P < 0.05 was considered
statistically significant. GraphPad Prism software (GraphPad Software, Inc., La Jolla,
CA) was used for all statistical analyses.

Results
CONPs facilitate RT-Induced Hydrogen Peroxide Production Favoring Lower than
Normal pH
To characterize H2O2 induction in vitro by RT, water or PBS of varying pH (pH
7.4, pH 5 and pH 3) was exposed to serial doses of ionizing radiation (5-30 Gy) and
relative H2O2 production was determined (Figure 1A).The results show a RT dosedependent increase in H2O2 production immediately following RT exposure in all
conditions to a similar degree. The basal as well as post-RT levels of H2O2 in acidic
buffer were considerably lower than those at neutral pH, suggesting that the
autodismutation activity was lower at acidic pH. In acidic pH CONPs produced H 2O2
while scavenging superoxide radicals with an equation of O 22-. + CeO2-x(Ce3+) +2H+
H2O2+ CeO2 (Ce4+), indicating that in acidic pH, CONPs produce H2O2 while scavenging
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superoxide radical. The size and shape of the CONPs were also determined by TEM
(Figure 1B).
The impact of CONPs on radiation-induced radical production has been
suggested but not documented. To characterize this, we first tested if prior presence of
CONPs affects H2O2 induction at neutral pH by RT (Figure 2A & 2B and Figure S1A &
S1B). CONPs suspended in water at serial concentrations (up to 200 µM) were exposed
to 3 or 5 Gy RT. We noticed that CONPs alone, regardless of concentration, did not
alter baseline H2O2 levels in water (pH 7.4) (data not shown). We found that the prior
presence of CONPs prevented RT-induced H2O2 production in the water compared to
non-CONP treated groups, although a slight increase in H2O2 levels was observed with
CONPs at a concentration less than 10 µM. Similar changes were observed when
CONPs were added 1 hour (Figure 2C & 2D and Figure S1C & S1D) or 24 hours
(Figure 2E & 2F and Figure S1E & S1F) after RT. It should be noted that the H 2O2
induction at neutral pH (7.4) is comparable between water and PBS solution (Figure
S2), and that the presence of CONPs in the assay reaction or removal of CONPs from
the reaction does not change the readout for H2O2 levels (Figure S3). These results
suggest that the neutral pH environment seems to favor the catalase-mimetic H2O2
scavenging activity over the SOD-mimetic H2O2 producing activity of CONPs.
The neutral pH mimics the cellular environment of a normal cell. A cancer cell
such as the L3.6pl human pancreatic cancer cells usually maintains an acidic
intracellular pH (Figure S4).

To assess impact of CONPs on RT-induced H2O2

production at acidic pHs, PBS-buffered solution at pH 5 or pH 3 was incubated with
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CONPs for 24 hours prior to RT. We found that under these acidic conditions, treatment
with CONPs helped maintain the persistent high levels of H2O2 (Figure 3A-3D and
Figure S5). Combined with the data obtained at the neutral pH, these results indicate
that the acidic environment favors the SOD-mimetic H2O2 producing (or superoxide
radical scavenging) activity over the catalase-mimetic H2O2 scavenging activity of
CONPs. It has recently been suggested that the switch between the SOD-mimetic and
catalase-mimetic activities of CONPs depends upon the oxidation state of CONPs with
Ce3+ state favoring the H2O2 production and Ce4+ state favoring the H2O2 scavenging.
To determine the potential effect of pH on the role of CONPs of either oxidation state,
we added the Ce3+ or Ce4+ CONPs into water solution of pH 7, pH 5 or pH 3 and
examined their superoxide radical or H2O2 scavenging activity (Figure 3E & 3F). The
Ce3+ CONPs showed high activity on superoxide scavenging (Figure 3E) but little or no
activity on H2O2 scavenging regardless of pH changes (Figure 3F). Conversely, the Ce4+
CONPs showed little or no activity on superoxide scavenging at both pHs (Figure 3E)
but high activity on H2O2 scavenging at pH 7 which decreased dramatically at pH 3
(Figure 3F). These results imply that the acidic environment plays a major role in
accumulating H2O2, presumably through increasing the Ce4+ to Ce3+ switch or Ce3+/Ce4+
ratio.
CONPs Increase RT-Induced ROS Levels in Pancreatic Cancer Cells
Next, we investigated whether and to what extent CONPs might affect radiationinduced ROS production in pancreatic cancer cells and normal pancreatic cells. Our
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results show a persisting increase (> 2-fold, at 0.5 hour through 24 hours post RT) in
radiation-induced ROS production in L3.6pl cells pretreated with CONPs (10 µM) for 24
hours (sufficing for CONP uptake by cells (23,27,28) before 5 Gy RT exposure, as
compared to cells exposed to radiation alone (Figure 4A & 4B; P=0.006). In sharp
contrast, the same treatment led to a constant decrease (> 50%) in radiation-induced
ROS production in hTERT-HPNE cells (Figure 4A & 4B P=0.006). The difference was
even greater if the ROS levels were compared between the cancer and normal cells
(Figure 4B; P < 0.001). Consistent with the buffer only based experiments shown in
Figure 3, these results suggest that radiation action on pre-existing CONPs is critical for
ROS production selectively in the cancer cells, presumably by increasing the Ce 3+/Ce4+
ratio in the acidic cellular environment. This was further supported by the little effect of
post-RT treatment of the cells with CONPs (Figure 4C & 4D). Notably, CONP treatment
alone (Figure 4B, 0 hour post-RT) could also increase the ROS levels in the cancer
cells but decrease it in the normal cells, suggesting an interesting possibility that the
basal oxidation state or Ce3+/Ce4+ ratio of CONPs depends upon the acidity of the
cellular environment. While the ROS data show CONPs do act as an antioxidant under
the condition of normal cells, the radicals generated by RT seem to eventually
overwhelm the antioxidant ability of the CONPs. This is evidenced by the ROS levels
24 hours versus 3 hours post RT, further supporting the potentially differential impact of
RT on the Ce3+/Ce4+ ratio in the acidic cancerous versus neutral normal cellular
environment. Nevertheless, the CONP-then-RT treatment seems to be the favorable
strategy to enhance ROS levels selectively in the cancer cells.
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CONPs Enhance RT-Induced Cell Death in Pancreatic Cancer Cells
L3.6pl and hTERT-HPNE cells were incubated with CONPs concentrations (10
µM) for 24 hours followed by 5 Gy RT and subject to cell viability assays (Figure 5A).
CONPs alone induced cancer cell death (12.5%, P=0.0055) compared to control (no
treatment) and sensitized L3.6pl cells to 5 Gy RT resulting in an additional 12.9%
(P=0.0196) increase in cell death compared to cells exposed to radiation alone.
Excitingly, CONP treatment caused neither statistically significant increase in cell death
nor sensitization to RT in the normal cells. Consistent results were obtained by another
independent, clonogenic assays (Figure 5B & 5C). These results indicate that CONPs
alone can induce cell toxicity and enhance sensitization to RT selectively in acidic
cancer cells.
CONPs Enhance Growth Inhibition and Apoptosis Induced by RT in vivo in Human
Pancreatic Tumors
To determine if CONPs can increase pancreatic cancer cell sensitivity to RT in
vivo, we examined the effect of CONPs on orthotopic L3.6pl tumor growth in athymic
nude mice (Table 1). The data show that, compared to RT alone, the addition of CONP
treatment to RT caused a dramatic decrease in tumor weight (P = 0.0112) and tumor
volume (P = 0.0006). Interestingly, like RT alone, CONPs alone also resulted in a
striking decrease in tumor volume although the change in tumor weight was marginal.
While the mean tumor volume may suggest that the synergistic effects of the cotreatment were only marginally better than the CONPs or RT alone, it is not necessarily
indicative of the efficacy of the co-treatment. In the co-treated group, 50% of the mice
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had tumors with a volume less than 1000 mm 3, whereas no other group had a single
mouse with a tumor that small. Body weight was not changed among all treatment
groups as compared with control mice. These results suggest that CONPs can act
synergistically to enhance RT-induced inhibition of the tumor growth without causing
obvious undesired toxicity to the host.
To determine the mechanisms underlying the tumor growth inhibition, effects of
CONPs (alone or in combination with RT) on apoptosis were analyzed on the tumors
harvested from the different treatment groups. H & E (Figure 6A, panels a-d) and
TUNEL staining (Figure 6A, panels e-h) revealed that there was no apoptosis in
untreated control tumors (Figure 6Aa & 6Ae). Apoptosis was increased by 25 times in
RT-treated tumors (Figures 6Ab, 6Af and 6B), 120 times in CONP-treated tumors
(Figures 6Ac, 6Ag and 6B), and 180 times in CONPs plus RT treated tumors (Figures
6Ad, 6Ah and 6B), with all groups being statistically significantly different from one
another following TUNEL quantification (Figure 6B). The apoptosis appeared to be
restricted to the tumor tissue, suggesting that CONPs selectively sensitize tumor cells to
and protect normal cells from RT-induced apoptosis.
Discussion
This is the first study to examine a potential role of CONPs as an adjuvant for
radiation therapy to treat pancreatic cancer. The results demonstrate that CONPs
selectively sensitize human pancreatic cancer cells to RT acting as pro-oxidant and
induce apoptosis due to acidic tumor cell environment.
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The fact that acidic environment allows lower basal levels of H 2O2 and more
resistance to RT induction of H2O2 than neutral environment (see Figure 1) suggests
that the autodismutation activity is lower in acidic than neutral environment. This could
make a significant, if not major, contribution to resistance to RT by (acidic) tumor cells
as well as RT-induced toxicity to (neutral) normal tissues. Therefore, increasing SOD
activity in tumor cells and H2O2 scavenging activity in normal cells appears to be a key
to sensitizing cancer cells to RT.
RT alone is known to kill normal cells in addition to cancer cells, as also
demonstrated in Figure 5A. This is not surprising given that

cancer cells have

developed some mechanisms such as high acidity that make them more resistant to RT
than normal cells. This is also the very reason why RT sensitization therapy is critical so
that the same dose of RT can kill much more cancer cells without increasing the side
effect on normal cells. The pre-treatment with CONPs has achieved exactly such a goal
of sensitizing the cancer cells selectively to the subsequent RT (Figure 5 and 6) without
increasing the RT toxicity to the normal cells (Figure 5A). Previous studies have shown
that CONPs are capable of acting as both a SOD mimetic to scavenge superoxide
radicals (49) and a catalase mimetic to scavenge H2O2 (14,16), and that acidic pH
promotes SOD mimetic activity of CONPs while inhibiting catalase mimetic activity,
resulting in increased accumulation of H2O2 (20). Consistently, our results further
demonstrate that the acidity-dependent differential role of Ce3+ versus Ce4+ oxidation
state of CONPs is a critical mechanism in the regulation of the activity switch between
SOD mimetic and catalase mimetic and subsequent H2O2 accumulation (see Figure 3).
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This could explain why CONPs alone was almost as toxic as RT to the cancer cells but
showed little or no toxicity to the normal cells (Figure 5A). This finding points out an
important role of CONPs as a stand-alone therapeutic for cancer treatment. More
importantly, our results also indicate that RT further increases the SOD mimetic activity
and decreases the catalase mimetic activity of CONPs in acidic environment (see
Figure 2 and Figure 3), suggesting that RT may induce a switch of oxidation states from
Ce4+ to Ce3+ of CONPs favorably in acidic tumor environment, which is supported by the
chemical reaction equation of O22-. + CeO2-x(Ce3+) +2H+ H2O2+ CeO2 (Ce4+). Indeed,
we have observed a few percent change in Ce3+/Ce4+ ratio at neutral pH induced by
radiation (data not shown). It remains unknown and interesting how the SOD activity of
Ce3+ and catalase activity of Ce4+ are differentially regulated by different pH and to what
extent RT can switch the oxidation states from Ce4+ to Ce3+ at acidic pHs.
It is not known whether the acidic cellular environment also determines a
preferential uptake of CONPs into cancer cells. The differential role and oxidation state
of CONPs in acidic versus neutral pH environment make the implication of CONP
uptake into cancer versus normal cells more complicated. Assuming that as postulated
CONPs act primarily as a producer of H2O2 in (acidic) cancer environment and a
scavenger of H2O2 in (neutral) normal tissues, one would wish both the cancer and
normal cells take up sufficient amount of CONPs during the combination therapy. This
would make CONPs a ‘super sensitizer’ of RT which not only sensitizes cancer cells to
the therapeutic effect of RT but also desensitizes normal cells to the toxic side-effect of
RT. On the other hand, RT could kill the cancer cells and normal cells by distinct
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mechanisms which could interpret why CONPs reduce ROS levels in the normal cells
(Figure 4A) but fails to reduce the killing effect of RT on the cells (Figure 5A). Indeed, in
addition to apoptosis, mitotic cell death accounts for a significant portion of radiation
induced cytotoxicity. When this death mechanism fails to kill, the survived cancer cells
become more resistant to RT. This mechanism also poses a risk of aneuploidy and
oncogenesis in the normal cells that have survived the undesired exposure to RT. Given
that ROS pathways can induce both mitotic and apoptotic cytotoxicity, it will be
interesting to determine whether or not CONP treatment also sensitizes the cancer cells
to RT-induced mitotic cell death as well.
Previous work has documented the differential uptake of CONPs by lung cancer
and normal cells in culture (16). However, it remains very challenging to assess CONP
uptake in vivo or in situ by tumor versus normal tissues including its levels, distribution,
oxidation states as well as subcellular versus extracellular localizations and so on.
Furthermore, in addition to regulating ROS, CONPs likely play many other biological
roles to be identified in the cells or tissues. Further addressing these ‘nanodynamic’ and
‘nanokinetic’ issues would enhance the interpretation of the pre-clinical therapeutic role
of CONPs.
It would be interesting to test whether the H2O2 accumulation is the primary factor
contributing to the tumor selective apoptosis (see Figure 6) and whether the apoptosis
occurred to the cancer cells only, the tumor stromal cells only or both. One of the tumorassociated stromal cell types is vascular endothelial cells which are the building blocks
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of tumor angiogenesis that is in turn essential for aggressive tumor growth as well as
metastasis. Since all these processes are closely favored by hypoxia-induced
acidification within tumor microenvironment, both intracellular and extracellular, of the
vast majority types of cancer, CONPs could also play a role selectively against these
processes as well of tumor progression of many cancer types including pancreatic
cancer. Experiments are in progress to address these important questions.
Conclusion
In conclusion, this work demonstrates the novel role of CONPs to enhance RTinduced ROS production and cell death selectively in human pancreatic tumor cells
while protecting normal tissues from the toxic side-effect of RT depending upon the
environmental acidity. These findings suggest that CONPs may be further developed as
a novel tumor tissue sensitizer and normal tissue protectant to increase the therapeutic
index of RT for improving treatment of pancreatic cancer patients.
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Figures and Tables
A

Figure 1. Acidic pH is relatively resistant to H2O2 production compared to neutral
pH.
Water (pH 7.4) and PBS at indicated pHs were irradiated at indicated doses and H2O2
production was examined by Amplex Red Assay. *P<0.05 compared to water exposed
to that RT dose. B, TEM analysis of CONPs. Left panel shows TEM image of the
CONPs of size between 5-8 nm (inset, high magnification images). Right panel shows
selected area of electron diffraction pattern of the CONPs where A (111), B (200), C
(220), D (311), E (222) and F (400) are the different crystal planes of fluorite crystal
structure.
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Figure 2. At neutral pH CONPs generally decrease RT-induced H2O2 production.
(A & B) CONP suspensions of serial concentrations up to 200 μM in H2O or PBS at
neutral pH (Figure S2) were irradiated at indicated doses. H2O2 production was
determined at indicated time points post-RT (response to all the concentrations and
time-course response in Figure S1A-B). (C & D) H2O was irradiated at indicated doses.
After 1 hour CONPs were added up to 200 μM. H2O2 production was then determined at
indicated time points post-RT (see response to all the concentrations in Figure S1C &
S1D). (E & F) Water was irradiated at indicated doses. After 24 hours CONPs were
added up to 200 μM. H2O2 production was then determined at indicated time points
post-RT (see response to all the concentrations in Figure 21E & S1F).*P < 0.05
compared to 0 μM CONP at that time point.
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Figure 3. Under acidic conditions CONPs enhance H2O2 production and lose
H2O2 scavenging activity.
(A-D) CONPs of serial concentrations (up to 200 μM) were included in acidic PBS
solutions at indicated pHs for 24 hours followed by RT at indicated doses. H2O2
production was determined at indicated time points post-RT (see response to all the
concentrations and time course response in Figure S4 A-D). *P < 0.01 compared to 0
μM at the same time point. (E & F) CONPs with predominant Ce3+ and Ce4+ on the
surface were included in water at indicated pHs for indicated periods of time before
concentration of superoxide radical (E) or H2O2 (F) was determined using a SOD assay
kit and Amplex Red assay kit, respectively as described in Methods.
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Figure 4. CONP treatment prior to, but not post, RT increases RT-induced ROS
levels in acidic pancreatic cancer cells and decreases RT-induced ROS levels in
neutral pancreatic normal cells.
(A & B) The cancer (L3.6pl) and normal hTERT-HPNE cells were treated with (CONP)
or without (Ctrl) CONPs for 24 hours followed by 5 Gy RT. ROS levels were then
determined and compared between the cells at indicated times. Relative fold changes
were normalized to the control groups. (C & D) The cells were treated with 5 Gy RT for
24 hours prior to CONP treatment. ROS levels were then determined and compared
between the cells at indicated times. Relative fold changes are normalized to the control
groups. *P < 0.001. The acidic cancer cellular environment relative to the neutral normal
cellular environment was confirmed (see Figure S5).
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Figure 5. CONP pre-treatment selectively sensitizes pancreatic cancer cells to RTinduced cell death in culture.
(A) Indicated cells were pre-treated with 10 μM CONPs for 24 hours followed by RT at 5
Gy. Cell viability was determined 96 hours post-RT. Cell death was normalized to
untreated group. (B & C) L3.6pl cells were treated similarly as in A. Immediately after
the treatment, cells were detached, replated and grown for 7 days before colonies were
counted.
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Figure 6. CONPs enhance tumor cell apoptosis in vivo.
(A-D) Histologic evaluations using hematoxylin and eosin (H&E) staining. (E-H) TUNEL
staining of apoptosis cells in situ. Tumor cell implantation and treatment of mice are
described in Table 1. Tumor tissues along with adjacent normal pancreatic tissues were
collected at the time when mice were sacrificed. Formalin-fixed and paraffin-embedded,
immediately adjacent tissue sections were used for the staining. Immunopositive cells
for TUNEL staining were observed over 10 individual slides for each condition and
quantified using the NIH ImageJ software to determine the number of TUNEL positive
cells per field of view.
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+
+

Table 1. CONPs increase sensitivity to radiation-induced inhibition of human
pancreatic tumor growth.

6

*L3.6pl human pancreatic cancer cells (1 x 10 ) were injected into the pancreas of nude
mice. Groups of mice were treated with i.p injections: vehicle solution or CONP (15 µM:
0.01mg/kg) twice weekly for 6 weeks. Sub-groups of mice also received fractionated
radiation therapy (5 Gy) three times per week (total 30 Gy) during weeks 3 and 4. All mice
were sacrificed on day 32. Tumor weight and volume analysis were performed as
described in methods.
†
P< 0.05 compared to radiation treatment.
ǂ
P < 0.05 compared to control treatment.
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CHAPTER 3: CERIUM OXIDE NANOPARTICLES DO NOT INCREASE
RADIATION-INDUCED DNA DAMAGE IN PANCREATIC CANCER
CELLS
Introduction
It is known that ionizing radiation therapy kills cells via multiple mechanisms, as
irradiation has been shown to induce cell death through apoptosis, mitotic catastrophe,
and even senescence (59). In cell types which are prone to apoptotic cell death, such
as hematopoietic cells, apoptosis is the predominant cell death pathway induced by
exposure to radiation (59). However, most solid human malignancies, such as
pancreatic cancer, generally lose pro-apoptotic mechanisms over the course of tumor
progression (59). As a result, mitotic catastrophe becomes the driving mechanism of
cell death induced by ionizing radiation in solid tumors, especially of epithelial origin
(60).
Mitotic catastrophe, or clonogenic cell death, occurs when unrepaired DNA
damage does not properly arrest the cell cycle (61) and, as a result, the cell dies during
or due to aberrant mitosis (59). Just as many malignant cells lose pro-apoptotic
mechanisms, they often also become deficient in cell cycle checkpoints during
transformation and progression, which contributes to the chance for mitotic catastrophe
(61). The premature progression of the cell cycle through mitosis results in the abnormal
division of chromosomes during cell division, often leading to giant cells with unusual
nuclear morphology, multiple nuclei, or multiple micronuclei (59). The nuclear and
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chromosomal abnormalities eventually doom the cell to death through delayed
apoptosis or necrosis.
We have previously established that CONPs are able to sensitize pancreatic
cancer cells to RT-induced cell death, but the mechanism by which that sensitization
occurs remained unknown. The induction of DNA damage is the first step in a cell’s
progression to mitotic catastrophe resulting from radiation exposure. If CONPs are able
to induce DNA damage either by directly oxidizing DNA or by some interaction with the
effects of RT, this could explain the sensitization phenomenon we have observed in
pancreatic cancer cells. Therefore, this study determined the ability of CONP treatment
to influence RT-induced DNA damage in pancreatic cancer cells as a potential
mechanism of sensitization.
Methods and Materials
Cell Culture and Reagents
The normal pancreatic cells (hTERT-HPNE) were obtained from American Type
Culture Collection (ATCC) and maintained in 3:1 glucose free DMEM:M3 Base medium,
supplemented with 10% fetal bovine serum, 100 µg/mL gentamycin, and 1 g/L dextrose.
The human pancreatic cancer cell lines L3.6pl (50) and Panc1, also obtained from
ATCC, were cultured in DMEM. Both cell mediums were supplemented with 10% fetal
bovine serum and 100 µg/mL penicillin-streptomycin mixture (GIBCO) and maintained
at 37oC and 5% CO2. CONPs were purchased from NanoScale Corporation
(Manhattan, KS) or synthesized as previously described (51).
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Comet Assay
Human pancreatic cancer cells (L3.6pl and Panc1) and normal human pancreatic
epithelial cells (hTERT-HPNE) were plated in 10 cm dishes and let attach overnight.
Cells were then treated with 0 0r 10 µM CONPs. 24 hours later, cells were exposed to 0
or 5 Gy RT using a 160-kV cell culture and small animal irradiator (Kimtron Inc.,
Woodbury, Connecticut). Cells were trypsinized immediately following RT and subjected
to single cell electrophoresis (CometAssay®, Trevigen) according to the manufacturer’s
protocol, including control cells with predetermined amounts of DNA damage purchased
from Trevigen with the kit.
Results
CONPs Do Not Impact RT-Induced DNA Damage in Pancreatic Cancer Cells in vitro
L3.6pl and Panc1 pancreatic cancer cells exposed to RT, CONPs, or the
combination of CONPs followed by RT all displayed some degree of DNA damage, as
indicated by the ratio of the amount of DNA in the comet head to the amount of DNA in
the comet tail (Figure 7A-B). However, the combination therapy did not display additive
effects; CONPs followed by RT did not induce a greater amount of DNA damage than
RT alone. Additionally, the amount of DNA damage that resulted from exposure to RT
correlated with the resistance of the cancer cell line to radiation-induced death. Panc1
cells, acknowledged to be more radiation resistant, showed less DNA damage
demonstrated by the migration of DNA into the tail, than L3.6pl, which is a
comparatively radiation-sensitive cell line. As this assay was completed immediately
41

following RT exposure, the effects of DNA repair in response to CONP treatment can be
excluded.
CONPs Inhibit RT-Induced DNA Damage in Normal Pancreatic Epithelial Cells in vitro
In contrast to the lack of effect of CONPs on RT-induced DNA damage in
pancreatic cancer cells, normal hTERT-HPNE cells were responsive to pre-treatment
with CONPs prior to RT. Normal pancreatic epithelial cells that were pre-treated with 10
µM CONPs before exposure to 5 Gy RT displayed significantly less DNA damage,
indicated by the tail moment, compared to cells exposed to RT alone immediately
following RT exposure (Figure 7C). Further, CONPs alone did not induce any DNA
damage in normal cells, indicating the non-toxic properties of CONPs in normal cells
and the protective capabilities of CONPs in normal pancreatic epithelial cells exposed to
RT.
Discussion
While differing reports exist about the impact of CONPs on cells in culture,
CONPs have been shown to be toxic to various types of cancer cells (19,20,36).
Several mechanisms for the toxicity to cancer cells have been suggested. CONPs have
been shown to induce oxidative stress, glutathione oxidation, lipid peroxidation, and
membrane damage in some cancer cells (19,36). However, CONP-induced DNA
damage has not been implicated as a mechanism of CONP toxicity in any cell types.
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As discussed, there is uncertainty about the fate of CONPs once inside a cell.
Therefore, the intracellular proximity of CONPs to DNA remains unclear. Several
studies have found that CONPs accumulate in the cytoplasm without translocation to
the nucleus (20,21), yet CONPs have also been identified accumulating in the perinuclear space (25). Other groups were able to detect CONPs localized to the
mitochondria, lysosomes, and endoplasmic reticulum, in addition to a diffuse distribution
throughout the cytoplasm and nucleus (23). CONPs in the nucleus are far more likely to
be able to induce DNA damage than CONPs compartmentalized elsewhere in the cell.
As Figure 1 demonstrates, CONP treatment alone was able to induce moderate DNA
damage selectively in pancreatic cancer cells, potentially due to inherent oxidase
activity. However, CONP treatment did not induce any DNA damage in normal
pancreatic epithelial cells. This difference may be attributable to the differential activity
of CONPs at differing pH. CONPs at acidic pH similar to that of a cancer cell have been
shown to increase H2O2 levels by performing only SOD mimetic activities. In contrast,
CONPs at the neutral pH of a healthy cell reduce ROS levels by acting as both an SOD
mimetic and a catalase mimetic to remove H2O2 from the cell (19). Therefore, only
under acidic conditions found in cancer cells, CONPs may be able to directly induce a
low level of DNA damage. The differential properties of CONPs in cancer and normal
cells add to their potential therapeutic applications and further support their pursuit as a
novel radiation adjuvant.
As expected, RT-induced DNA damage was evident in each of the cell types
exposed to radiation. However, CONP and radiation treatment did not have a
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synergistic effect on the cancer cells; co-treatment of cancer cells did not increase the
amount of DNA damage above that induced by RT alone. In contrast, CONP treatment
dramatically decreased the amount of initial DNA damage in normal pancreatic
epithelial cells exposed to RT. The opposing responses suggest that radical scavenging
by CONPs is sufficient to decrease DNA damage, but radical production by CONPs is
not sufficient to induce DNA damage resulting in sensitization.
Of note, our other assays have also demonstrated protection of normal cells
exposed to RT by CONPs, albeit transient. This assay was completed immediately
following RT exposure, which would be well within the timeframe of transient protection.
It would be interesting to determine if CONPs are able to influence the levels of DNA
damage in normal cells, long term. However, later experiments that determine viability
will suggest that long term protection of normal pancreatic epithelial cells is not
achieved.
Despite the differential impact of CONPs to protect normal pancreatic cells from
DNA damage, but not cancer cells, the lack of sensitization of cancer cells to DNA
damage suggests that other cellular mechanisms must be involved. Therefore, a cellular
response separate from mitotic catastrophe must be responsible for the CONP-induced
sensitization of cancer cells to RT, likely apoptosis.
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Conclusion
In conclusion, CONPs showed protection of normal hTERT-HPNE cells against
the DNA damaging effects of radiation. However, although RT alone induced DNA
damage, CONPs did not significantly impact RT-induced DNA damage in pancreatic
cancer cells. Therefore, enhanced DNA damage is not the mechanism by which CONPs
sensitize cancer cells to RT and a different mechanism or pathway must be responsible
for the sensitization phenomenon observed in pancreatic cancer cells.
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Figure 7. CONPS do not alter RT-induced DNA damage in pancreatic cancer cells.
Cells were treated with 0 or 10 µM CONPs for 24 hours, followed by exposure to 0 or 5
Gy RT. Cells were immediately tripsinized following RT and used for CometAssay®. (A)
L3.6pl and (B) Panc1 pancreatic cancer cells did not show sensitization to RT-induced
DNA damage by CONP treatment. (C) CONPs protected normal hTERT-HPNE cells
from RT-induced DNA damage. *P<0.001.
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CHAPTER 4: CERIUM OXIDE NANOPARTICLES SENSITIZE CANCER
CELLS TO RADIATION BY INDUCING ROS ACTIVATION OF JNK AND
APOPTOSIS
Introduction
Current predictions indicate that one in two men and one and three women in the
United States will develop cancer at some point in his or her lifetime (4). Of the nearly
600,000 cancer related deaths in the USA each year (1), roughly 30,000 of those
deaths are caused by pancreatic cancer (3). Only 15-20% of pancreatic cancer patients
present with surgically resectable disease; roughly 20% of patients with surgically
resectable disease survive to 5 years post operation (3). The main treatment suggested
for patients with locally advanced, or surgically unresectable, pancreatic cancer is a
combination of chemotherapy and radiation therapy (3). Chemoradiation has been
shown to both extend survival and decrease the pain commonly associated with
pancreatic cancer (3). However, current chemotherapy and radiotherapy agents for
advanced pancreatic cancer have shown minimal lasting impact, as most patients show
signs of progression and metastatic development within only a few months of
completing treatment (3).
While surgical resection physically removes the tumor cells, chemotherapy and
radiation therapy attempt to induce tumor cell death while the tumor is still inside a
patient. It has been previously shown that tumor cell redox status plays a key role in
response to death stimuli, with treatments that generate significant amounts of H 2O2
more effectively inducing cell death execution (62). Cell death can be executed by cells
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through multiple mechanisms in response to various signals, with the two main death
mechanisms induced in cells by exposure to radiation therapy (RT) being mitotic
catastrophe and apoptosis (59). Apoptosis, or programmed cell death, is an essential
cellular process for the development and maintenance of normal cells and tissues in the
body (63). Malfunctions in the apoptotic machinery have been linked to a variety of
diseases, including cancer and worsening with the cancer progression. As cells move
through the neoplastic progression, they lose sensitivity to many of the apoptotic stimuli,
which may help explain why cancers in the early stages tend to be more sensitive to
chemotherapies and radiotherapy (63). Therefore, especially for cancers such as
pancreatic that are commonly diagnosed in late stages, it is critical to identify treatments
that are able to overcome the resistance of cancer cells to the available treatment
modalities.
Cerium oxide nanoparticles (CONPs) are a new compound currently being
pursued in pre-clinical trials for their potential use as a cancer therapy. Originally tested
for their ability to scavenge radicals and protect normal tissues from radiation-induced
damage associated with treating cancer in the head and neck (7), intestine (28), lung
(27), and breast (30), the application of CONPs has expanded beyond the mitigation of
the side effects of other cancer therapies. Several reports have documented the
inherent toxicity of CONPs to cancer cells of various origin, including alveolar epithelial
cancer cells (23), hepatocellular carcinoma cells (64), and pancreatic carcinoma cells
(19), among others. Studies have now established that CONPs can directly inhibit
squamous carcinoma cell invasion, as well as indirectly inhibiting invasion by blocking
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the formation of myofibroblasts (20). Other researchers have demonstrated CONPinduced inhibition of the growth and invasion in melanoma cells (65). A most recent
publication also established the anti-angiogenic properties of CONPs in an ovarian
cancer model (66). The testing of CONP-based cancer therapies is rapidly expanding,
both as the primary treatment and as an adjuvant treatment for already established
therapies.
Our previous publication demonstrates that CONPs possess inherent toxicity and
the ability to sensitize pancreatic cancer cells to radiation-induced cell death, without
negatively impacting the corresponding normal cells viability or radiosensitivity. CONPs
were also shown to selectively increase RT-induced ROS production in pancreatic
cancer cells. In the absence of significant changes in RT-induced DNA damage in
cancer cells (Figure 1), redox controlled apoptotic signaling was implicated as the driver
of CONP-induced radiosensitization. Herein, we establish one of the redox-responsive
apoptotic pathways responsible for the radiosensitization of pancreatic cancer cells by
CONPs.
Methods and Materials
Cell Culture
Normal pancreatic cells (hTERT-HPNE) were obtained from American Type
Culture Collection (ATCC) and maintained in 3:1 glucose free DMEM:M3 Base medium,
supplemented with 10% fetal bovine serum, 100 µg/mL gentamycin, and 1 g/L dextrose.
The human pancreatic cancer cell lines Panc1 (ATCC) and L3.6pl was cultured in
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DMEM. Both cell mediums were supplemented with 10% fetal bovine serum and 100
µg/mL penicillin-streptomycin mixture (GIBCO), with cells maintained at 37oC and 5%
CO2.
Generation of Stable Cell Lines
Wild type TRX1 (Addgene plasmid 21283) and TRX1 His C32S and TRX1 His
C35S (Addgene plasmids 21284 and 21285) constructs were transferred into the pKH3
vector to add a HA-Tag (67,68) and then into the lentiviral pLVPZ vector encoding
puromycin resistance. As previously described (69), the lentivirus was produced by
transfecting 293FT cells with the vectors, the media collected from the transfected
293FT cells were used to infect L3.6pl and Panc1 cells for three repeated times.
Positively infected cells were then selected with and maintained in medium
supplemented with 1 µg/mL puromycin. Protein expression was confirmed via western
blot for the HA-Tag. Puromycin was removed prior to caspase or viability assays.
Phospho-ELISA
L3.6pl cells were seeded into 10 cm dishes and let attach overnight. Cells were
then treated with 0 or 10 µM CONPs followed by exposure to 0 or 5 Gy RT 24 hours
later. 72 hours post RT, cells were collected and cell lysate was subjected to screening
with the PhosphoELISArray Multi-Analyte Kit for key pathways associated with human
cancer according to the manufacturer’s protocol (SA Biosciences, FEM-5001).
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Antibodies, Drugs, and Western Blot
Primary antibodies were purchased from Cell Signaling Technology (TRX #2429,
p-ASK1 #3765, p-JNK1/2 #9251, JNK1/2 #9252, Cleaved Caspase-3 #9664, HA-Tag
#3724, GAPDH #5174). Secondary antibodies were purchased from Invitrogen (Alexa
Fluor® 488 anti-rabbit #A-11034) and Santa Cruz (anti-rabbit #sc-2004). CONPs were
purchased from NanoScale Corporation (Manhattan, KS) or synthesized as previously
described (51).. For western blotting, cells were plated in 10 cm dishes and let attach
overnight. Media was then removed and replaced with media containing 0 or 10 µM
CONPs. 24 hours later, cells were exposed to 0 or 5 Gy RT with cell lysates collected
24-72 hours after radiation. Proteins were separated on 12.5% SDS-PAGE gels,
transferred to nitrocellulose membranes using the iBlot system (Invitrogen), and blotted
following standard procedures.
P-ASK1 Immunostaining
hTERT-HPNE, Panc1, and L3.6pl cells were seeded onto glass coverslips and
let attach overnight. Media was then removed and fresh media containing 0 or 10 µM
CONPs was added. 24 hours later, cells were exposed to 0 or 5 Gy RT. 4 hours post
RT exposure, coverslips were washed 2X in ice-cold PBS (5 min) and fixed in 10%
paraformaldehyde (20 min) at room temperature. Coverslips were then washed 3X in
ice-cold PBS (5 min) and permeabilized with ice-cold acetone (5 min) at -20oC.
Subsequent to 3 more washes (5 min) in ice-cold PBS, coverslips were blocked (5%
bovine serum albumin (BSA) in PBS) for 1 hour at room temperature followed by
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incubation in primary p-ASK1 antibody (1:50 - 1:100) at 4oC overnight (Cell Signaling,
#3765). Coverslips were then washed 3X (5 min) in ice-cold PBST, followed by
incubation Alexa Fluor® 488 anti-rabbit secondary (1:100 – 1:200) at room temperature
for 1 hour (Invitrogen). Finally, coverslips were washed 3X (5 min) in ice-cold PBS and
mounted using ProLong® Gold antifade reagent with DAPI. A 10X objective on a Nikon
E400 microscope (Nikon Instruments, Melville, NY) was used to capture random fields
on each slide (slides stained in triplicate). P-ASK1 positive cells were quantified using
Image-J software (NIH).
Caspase Activation Analysis
hTERT-HPNE, Panc1, and L3.6pl cells were seeded onto white-walled, clearbottomed, 96 well plates (2,000 cells/well) and let attach overnight. Media was then
removed and media containing 0 or 10 µM CONPs was added. 24 hours later, cells
were exposed to 0 or 5 Gy radiation. At 24-48 hours post radiation, caspase 3/7
activation was determined via Caspase-Glo® 3/7 Assay (Promega) following the
manufacturer’s protocol. Caspase activity was normalized to cell viability, which was
determined with CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Data was
normalized to control (untreated) capsase levels for graphing.
JNK Inhibitor Studies
Panc1 and L3.6pl pancreatic cancer cells were seeded into 10 cm dishes and let
attach overnight. Media was then removed and replaced with media containing 0 or 10
µM CONPs and 20 µM specific JNK inhibitor (EMD #420119), added at the same time.
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Radiation treatment (0 or 5 Gy) and the subsequent analysis of caspase activation
(Caspase-Glo® 3/7 Assay, Promega) normalized to viability (CellTiter-Glo®
Luminescent Cell Viability Assay, Promega) were completed by the same protocol as
previously described. Additionally, the impact of the JNK inhibitor to mitigate radiationinduced cell death and CONP-driven radiosensitization was also determined from the
CellTiter-Glo Luminescent Cell Viability Assay (Promega) data, which was normalized to
control levels.
Orthotopic Injection of Pancreatic Cancer Cells in Athymic Nude Mice
Female athymic nude mice (NCI-nu) were purchased from the Animal Production
Area of the National Cancer Institute Frederick Cancer Research and Development
Center. The mice were housed and maintained in specific pathogen-free conditions in
facilities approved by the American Association for Accreditation of Laboratory Animal
Care and in accordance with current regulations and standards of the United States
Department of Agriculture, United States Department of Health and Human Services,
and the National Institute of Health. The mice of 4 to 6 weeks of age were used in
accordance under institutional guidelines with approved IACUC protocol. Human care of
the mice was thoroughly considered. To develop tumors, L3.6pl cells, as well as L3.6pl
cells stably expressing wild type TRX1, C32S mutant TRX1, and the empty pLVPZ
vector, were harvested from culture dishes and injected as previously described (5658).
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Therapy of Established Human Pancreatic Carcinoma Tumors Grown in the Pancreas
of Nude Mice
Mice were randomized immediately following injection of L3.6pl cells (1x106) into
the pancreas into two groups (n = 20) as follows: (a) twice weekly intraperitoneal (i.p.)
injections of saline in control groups; (b) twice weekly (Tuesday and Thursday) i.p
injections of CONPs (15 µM; 0.01 mg/kg). Two weeks later each group was randomized
into 2 sub-groups (n = 10) as follows: (c) continued with twice weekly i.p injections of
saline (for control group) or twice weekly i.p. injections of CONPs; (d) twice weekly i.p.
injections of saline or CONPs and thrice-weekly administration of 5 Gy radiation for 2
weeks (30 Gy total). All treatment groups continued to receive twice weekly i.p.
injections of saline (control) or CONPs for 2 additional weeks (for a total of 6 week
treatment). Mice were sacrificed at 8 weeks (day 56) and subjected to necropsy.
Tissues were analyzed for caspase 3 cleavage and JNK phosphorylation to correlate
with in vitro experiments.
Immunohistochemical Analysis
Paraffin-embedded tissues were used for p-JNK and cleaved caspase 3.
Sections (4 to 6 μm thick) were mounted on positively charged Superfrost slides
(Fischer Scientific, Co.) and dried overnight. Sections were de-paraffinized in xylene,
subjected to a graded series of alcohol [100%, 95%, and 80% ethanol (v/v) in deionized
H2O], and rehydrated in deionized water followed by PBS (pH 7.5). Slides were placed
at 97°C in 0.1 mol/L citrate buffer (pH 6.0) for 10 min to achieve antigen retrieval,
followed by washing with PBS that contained 0.1% triton and 0.1% BSA. Endogenous
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peroxidase was blocked with 3% hydrogen peroxide in PBS whereas nonspecific
binding was blocked with 10% normal horse serum and 2% BSA in PBS. The slides
were then incubated at 4°C in a moist chamber with either the p-JNK or cleaved
caspase 3 antibody (overnight). Slides were washed with PBS that contained 0.1%
triton and 0.1% BSA in PBS. The slides were then incubated with a peroxidaseconjugated mouse IgG secondary (Santa Cruz Biotechnology; 1:500 dilution, 1 hour), a
positive

reaction was visualized

by incubating the slides with

stable

3,3′-

diaminobenzidine (Invitrogen Corporation) for 8 to 10 min. Counterstaining was
achieved by rinsing the sections with two changes of tap water, placing them in Gill's
filtered hematoxylin (EMD Chemicals) for 5 min, then successively dipping into tap
water, acid alcohol (EMD Chemicals), tap water, lithium carbonate (EMD Chemicals),
and tap water. Slides were dehydrated by incubations in 95% ethanol, 100% ethanol,
and xylene, then mounted with Crystal Mount (Fischer Scientific, Co.). For each
antibody, the corresponding normal mouse IgG and horseradish peroxidase were used
as controls, and wash buffer was used as an additional control in immunohistochemistry
studies. Immunohistological microscopy was performed using a 40X objective on a
Nikon E400 microscope (Nikon Instruments, Melville, NY). Routine procedures were
used to capture images.
Statistical Analysis
The in vitro experiments were completed in triplicate and the data are presented
as mean ± SD. Statistical analysis was performed using Student's t test, assuming
equal variance, and P value was calculated based on two-tailed test. P < 0.05 was
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considered statistically significant. GraphPad Prism software (GraphPad Software, Inc.,
La Jolla, CA) was used for all statistical analyses.
Results
CONPs Drive RT-Induced JNK Activation in Cancer Cells
To determine the pathway activated in response to RT in cells pre-treated with
CONPs, a multi-analyte ELISA for activation of proteins in key pathways associated with
human cancer was performed on L3.6pl human pancreatic cancer cells exposed to
CONPs, RT, and the combination therapy. Of the screened targets, only JNK activation
was significantly increased by the combination of CONPs followed by RT (Figure 8A);
none of the other targets (AKT, Erk1/2, p53) displayed enhanced activation in response
to the pre-treatment with CONPs compared to RT alone (Figure S6A-C).
The ability of CONPs to drive RT-induced JNK activation, as determined by JNK
phosphorylation, was further assessed via western blot analysis of L3.6pl and Panc1
pancreatic cancer cell lines at various time points following RT (Figure 8A&B). The
activation of JNK was significantly increased in both cancer cell lines by 72 hours
following exposure to RT. In contrast, when JNK phosphorylation was determined in
normal pancreatic epithelial cells (hTERT-HPNE, Figure 8A&B), the opposite impact
was evident; pre-treatment with CONPs induced a slight decrease in JNK
phosphorylation in normal cells compared to the impact of RT alone. CONPs alone did
not induce significant JNK phosphorylation in either pancreatic cancer or normal
pancreatic epithelial cells.
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When basal expression and phosphorylation of JNK in untreated cells were
determined, both L3.6pl and Panc1 pancreatic cancer cell lines had higher total JNK
expression than the corresponding normal hTERT-HPNE cells (Figure 8D). Based on
the ratio of phosphorylated JNK (p-JNK) to total JNK, nearly all of the JNK present in
normal pancreatic epithelial cells was phosphorylated, i.e. activated. However, there
was some difference in amount of phosphorylated and total JNK in pancreatic cancer
cells, indicating that not all of the JNK present is activated in un-treated pancreatic
cancer cells. Interestingly, ratio of active to total JNK correlated with cellular expression
of thioredoxin 1 (TRX1) (Figure 8D), a redox sensing protein upstream of JNK. TRX1
overexpression by cancer cells compared to the corresponding normal cells was
confirmed via western blot. Additionally, normal cells in which a greater percentage of
the basal JNK is phosphorylated express lower levels of TRX1 compared to the
pancreatic cancer cells which expressed higher levels of TRX1 and lesser degree of
basal JNK phosphorylation.
CONP-Driven JNK Activation Mediates RT-Induced Apoptosis in Pancreatic Cancer
Cells
As JNK activation can be both pro- and anti- apoptotic, we next analyzed
caspase 3 and caspase 7 activation as markers of apoptotic cells in vitro. Caspase 3/7
activation increases over time in response to RT in both L3.6pl and Panc1 pancreatic
cancer cells. In L3.6pl cells, which are inherently more sensitive to RT-induced cell
death, CONP-enhanced caspase activation is not evident until 72 hours post RT
(P<0.01, Figure 9A). However, in Panc1 cells which are inherently more resistant to RT57

induced cell death, the CONP-induced increase apoptotic signaling is discernible by 48
hours post RT (P<0.01) and persists through 72 hours post RT (P<0.05, Figure 9B).
The data indicate enhanced, stable activation of apoptosis in both pancreatic cancer cell
lines.
Conversely, CONPs appear to delay caspase activation in normal pancreatic
hTERT-HPNE cells. At 48 hours post RT, caspase 3 and caspase 7 activation are
significantly decreased in cells pre-treated with CONPs compared to cells treated with
RT alone (P<0.01, Figure 9C). 24 hours later, at 72 hours post RT, there is no longer a
difference between the caspase activation in cells treated with or without CONPs prior
to RT, indicating that the CONP-induced protection of normal pancreatic epithelial cells
from RT-induced apoptosis is a transient phenomenon.
CONPs Drive RT-Induced ASK1 Activation in Pancreatic Cancer Cells
Apoptosis signaling kinase 1 (ASK1), a protein responsible for activating
apoptotic signaling through JNK, is directly downstream of the redox sensing protein
TRX1. Upon TRX1 oxidation, ASK1 dissociates and auto-phosphorylates to become
activated. Therefore, ASK1 phosphorylation provides the link between ROS induced
TRX1 oxidation and the activation of JNK to induce apoptosis. ASK1 phosphorylation
was determined 1 hour after RT exposure in each cell line (Figure 10A). L3.6pl cancer
cells pre-treated with CONPs showed greater than a 1.5 fold (P<0.0001) increase in
ASK1 phosphorylation over RT alone, while pre-treated Panc1 cancer cells exhibited a
greater than 3 fold increase (P<0.001) in ASK1 activation compared to only RT. RT
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alone was not able to induce significant ASK1 activation in either pancreatic cancer cell
line. CONPs alone did induce mild ASK1 activation in the same cell. Conversely, normal
hTERT-HPNE cells showed roughly a 4 fold decrease in ASK1 phosphorylation at the
same time point when pre-treated with CONPs compared to RT alone (Figure 9A).
Additionally, CONPs alone did not significantly alter ASK1 activation in normal
pancreatic epithelial cells compared to control (untreated) levels. (Figure 9B) Results
were quantified and graphed relative to control (untreated) p-ASK1 levels within each
cell line.
Bright field images of the p-ASK1 stained slides were used to confirm that all
slides contained approximately the same number of cells upon the completion of
staining (Figure S7). Staining results were quantified and graphed to illustrate the
differences in p-ASK1 positive cells (Figure 9B). Of note, none of the treatments
significantly impacted TRX1 expression. TRX1 expression was consistent across all
treatment groups within each cell line (Figure 9C).
CONPs Increase JNK Activation and Apoptotic Signaling in Vivo
To corroborate the apoptotic signaling observed in vitro, we next tested the
combination therapy on established pancreatic tumors in nude mice. JNK activation
(Figure 11 A-D) and caspase 3 cleavage (Figure 11 E-H) were determined in tumor
sections from mice receiving only saline injections, radiation alone, CONPs alone, or a
combination of CONPs and RT. Results clearly show increases in both JNK activation
(brown staining) and caspase 3 activation, induced by cleavage (brown staining), in
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each of the treatment groups compared to control (saline injected) mice. However, it is
also evident that the combination of CONPs and RT yielded the most significant
increase in both JNK activation and caspase 3 activation (Figure 11 D&H), showing a
dramatic increase over tumors from mice that received RT (Figure 11 B&F) or CONPs
(Figure 11 C&G) alone.
JNK Inhibition Mitigates CONP-Induced Radiosensitization of Pancreatic Cancer Cells
To determine if JNK activation was the molecular driver of CONP-induced
sensitization, we next used JNK inhibitors to block JNK activity in cells exposed to RT,
CONPs, or the combination therapy. Results showed that, in the presence of a JNK
inhibitor, caspase 3/7 activation and sensitization to RT-induced cell death were
completely mitigated in L3.6pl pancreatic cancer cells (Figure 12 A&C). Similarly, in
Panc1 pancreatic cancer cells, caspase 3/7 activation was significantly reduced and
sensitization to RT-induced cell death was completely alleviated when compared to
cells treated without the inhibitor (Figure 12 B&D). Results were confirmed with a
secondary inhibitor (Figure S8), demonstrating that JNK function is essential for CONPinduced radiosensitization in pancreatic cancer cells.
The ability of JNK to mediate CONP-driven RT-sensitization was further
confirmed via JNK knockdown with JNK1/2 siRNA. Confirmed via western blot 7 days
post transfection (to mimic the 96 hours post RT viability time point), knockdown of JNK
expression was achieved in Panc1 cells, whereas siRNA treatment of L3.6pl cells was
ineffective (Figure S9A). Following siRNA transfection, CONPs were only able to
60

moderately increase apoptotic signaling, as evidenced by minimal caspase 3/7
activation (Figure S9B). Further, pre-treatment with CONPs did not increase cell death
induced by RT under the siRNA JNK knockdown conditions (Figure S9C), again
confirming that JNK is a critical mediator of CONP-driven RT-sensitization in pancreatic
cancer cells.
TRX1 Oxidation is Required for CONP-Induced Radiosensitization of Pancreatic Cancer
Cells
To confirm if the TRX1-ASK1 pathway is the critical activator of JNK to mediate
radiosensitization by CONPs, we next used L3.6pl and Panc1 cell lines that stably
expressed wild type TRX1-HA, C32STRX1-HA, C35TRX1-HA, or the empty pLVPZ
vector. Protein expression was confirmed via western blot for HA expression by each
cell line (Figure S10). While wild type TRX1 should interact with ASK1 the same as
endogenously expressed TRX1, both mutant proteins are unable to become oxidized,
and therefore, constitutively bind to ASK1 preventing ASK1 activation and the
subsequent apoptotic signaling.
Data shows that the mutation of TRX1 blocks the increased apoptosis in parental
L3.6pl and Panc1 cancer cells pre-treated with CONPs (Figure 13). However, L3.6pl
and Panc1 cells displayed different responses to the overexpression of wild type TRX1.
In L3.6pl cells, increasing wild type TRX1 expression made the cells more sensitive to
RT as indicated by caspase 3/7 activation (Figure 13A) and cell death (Figure 13C).
Yet, in Panc1 cells, increased wild type TRX1 expression slightly reduced caspase
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activation (Figure 13B) without altering overall cellular sensitivity to RT-induced cell
death (Figure 13C).
Discussion
Once it was determined that CONPs did not alter the ability of RT to induce cell
death via DNA damage (Figure 1), but instead induced significant increases in ROS
exclusively in pancreatic cancer cells (Figure 5), apoptotic signaling was implicated as
the mechanism of sensitization (Figure 6-7). There are many pro- and anti- apoptotic
pathways within the cell, several of which have been determined to play key roles in
cancer development and progression, such as the AKT, ERK, and p53 pathways. AKT
activation has been linked to cancer cell growth, survival, and proliferation (70), as well
as correlated to the invasiveness of pancreatic cancers (71). ERK1/2 has been shown
to protect pancreatic cancer cells from apoptosis and promote progression through the
cell cycle (72). AKT and ERK1/2 signaling become activated in cancers. P53, a
canonical tumor suppressor gene which normally plays a key role in induced cell death
in response to significant DNA damage, becomes inactive in more than 60% of
pancreatic cancers (73). While AKT (74), ERK1/2 (62), and p53 (75) may all become
active in response to ROS, none were involved in the cellular response to CONP-driven
RT-induced ROS (Figure S6).
However, activation of the JNK pathway was significantly up-regulated in
pancreatic cancer cells by the combination of CONPs and RT. JNK activation can be
both pro- and anti- apoptotic, driving cell proliferation, survival, and differentiation, as
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well as apoptosis (76). It is generally accepted that the length and strength of JNK
activation determines whether it promotes survival or apoptosis, with transient activation
promoting survival and prolonged activation driving cell death (76). Unfortunately, the
time point at which activation becomes classified as “prolonged activation” is not clearly
defined. Yet, JNK activation generally induces apoptotic effects in cancer cells exposed
to RT (6). Caspase 3/7 activation is recognized as a hallmark of JNK induced apoptosis;
therefore, caspase 3/7 activation was used to determine if JNK activation was driving
apoptosis or survival. Increased caspase activity directly correlated with increased JNK
activation in both pancreatic cancer cells and pancreatic tumors treated with CONPs
and RT, suggesting that CONP-driven JNK activation resulted in apoptosis under the
co-treatment. In opposition, caspase activation was delayed in normal pancreatic
epithelial cells, suggesting CONP-mediated protection from RT.
Further, JNK activation was a promising candidate as the driver of sensitization
based on its redox responsive upstream regulators, mainly thioredoxin 1 (TRX1). When
cellular ROS, such as hydrogen peroxide, oxidize TRX1, a protein responsible for
converting oxidative stress into a cellular response, it dissociates from Apoptosis
Signaling Kinase 1 (ASK1). To become active, ASK1 must dissociate from TRX1 and
auto-phosphorylate. In turn, active ASK1 directly induces JNK activation leading to
apoptosis.
Our previous work has shown that CONPs induce H2O2 and ROS production in
pancreatic cancer cells (19). As such, we suggest that CONP-enhanced RT-induced
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ROS production results in the increased oxidation of TRX1 in pancreatic cancer cells to
mediate apoptosis. The overexpression of TRX1 by cancer cells (Figure 8D) increases
the total pool of TRX1 in the cell and, hence, the pool of reduced TRX1 available to
inhibit ASK1 activation. Increased ROS could further up-regulate the expression of ROS
scavenging proteins, like TRX1, which would be radio-protective. However, the various
RT and CONP treatments did not impact TRX1 expression in either pancreatic cancer
cells or normal pancreatic epithelial cells. TRX1 oxidation is necessary, but not
necessarily sufficient, to ensure ASK1 activation; another reduced TRX1 molecule could
bind the inactive ASK1 before activation occurs and prevent activation. Consequently,
ASK1 phosphorylation was chosen as the indicator of sufficient TRX1 oxidation to
induce apoptotic signaling. Further, ASK1-mediated sustained activation of JNK has
been shown to be required for ROS-induced apoptosis, with ASK1 knockout cells being
substantially more resistant to H2O2 (77). With pre-treatment of pancreatic cancer cells
with CONPs enabling RT to induce significantly more ASK1 phosphorylation than RT
alone, it can be suggested the CONP-driven TRX1 oxidation initiates the
radiosensitization of pancreatic cancer cells. Experiments to test this interesting
possibility in vivo are in progress.
Additional support for the significance of the ASK1/JNK signaling axis can be
found in the differential response of normal and cancer cells to the pre-treatment with
CONPs prior to RT. In contrast to the increase in ASK1 activation and caspase
activation in cancer cells, CONPs appear to confer transient protection to normal
pancreatic epithelial cells. CONPs have demonstrated the ability to temporarily
64

decrease radical production in response to radiation (Figure 5) but were not able to
protect normal cells from radiation induced cell death long term (Figure 6). Similarly,
CONPs were able to mitigate initial ASK1 activation and the resulting downstream
caspase activation; however, caspase activation eventually recovered to the level of
cells treated with RT alone. The phenomenon of transient radical scavenging in normal
cells was suggested to result from the production of ROS eventually exceeding the
radical scavenging capacity of CONPs, which would correspond with the delay in
caspase activation.
The ability of CONPs to protect normal cells or sensitize cancer cells to RT is,
most likely, intimately related to the uptake and localization of CONPs in particular cell
types. The concentration of CONPs in a cell may be a key determinant in the degree of
radical generation or scavenging. Unlike other canonical radical modulators which
require a 1:1 ratio between scavenging molecule and radical, CONP surface chemistry
enables a single nanoparticle to interact with multiple radicals, potentially making
activity an exponential function of concentration. Additionally, as pH has been shown to
play an important role in what radical manipulation properties CONPs exhibit, the
localization in acidic or neutral cellular compartments could significantly impact CONP
intracellular activity. Currently, the means to determine uptake requires highly
specialized machinery and the ability to determine localization of individual particles
remains elusive, rendering these important questions difficult to answer at this time.
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Conclusion
In conclusion, this work characterizes the mechanism by which CONPs enhance
RT-induced cell death selectively in human pancreatic tumor cells by activating the
redox sensing machinery in the cell. These findings provide further insight into the
cellular implications of CONP-based therapies, especially in conjunction with RT or
other potential radical inducing agents. Overall, this work supports the pursuit of CONPs
as a novel tumor tissue sensitizer to increase the therapeutic index of RT to benefit
pancreatic cancer patients.
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Figure 8. CONPs drive RT-induced JNK activation in pancreatic cancer cells.
(A) L3.6pl pancreatic cancer cells were treated with 10 μM CONPs followed 24 hrs later
by 0 or 5 Gy RT. Lysate was collected 72 hrs post RT for ELISA analysis, which showed
significantly increased JNK activation. (B-C) Pancreatic cancer cells (L3.6pl or Panc1)
and normal pancreatic epithelial cells (hTERT-HPNE) were treated in identical fashion
with lysate collected 24-72 hrs post RT. Western blot analysis showed (B) p-JNK1 and
(C) p-JNK2 levels increased in L3.6pl and Panc1 cells, but not hTERT-HPNE cells by
72 hrs post RT. (D) Basal expression of p-JNK, JNK, and TRX in untreated cells was
determined.
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Figure 9. CONP-enhanced JNK activation induces apoptosis in pancreatic cancer
cells.
Cells were treated with or without 10 μM CONPs for 24 hours followed by 0 or 5 Gy RT.
Caspase 3/7 activation was then determined 48 or 72 hours post RT by Caspase Glo
assay, normalized to viability, and graphed relative to control (untreated) groups. (A)
L3.6pl and (B) Panc1 cancer cells showed increased caspase 3/7 activation in response
to the co-treatment. (C) Normal hTERT-HPNE cells displayed a transient protection
from RT-induced caspase activation, but the protection was not lasting. *P<0.05,
**P<0.01.
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Figure 10. CONP pre-treatment increases RT-induced ASK1 activation in
pancreatic cancer cells.
(A) Pancreatic cancer cells (L3.6pl and Panc1) and normal pancreatic epithelial cells
(hTERT-HPNE) were pre-treated with 0 μM or 10 μM CONPs for 24 hours followed by
exposure to 0 Gy or 5 Gy RT. 4 hours later, cells were fixed and stained for p-ASK1.
Representative images are shown. (B) The number of fluorescent cells in 10 fields of
view per condition, per cell line was determined and normalized to control (untreated)
levels. (C) Lysate from cells treated in identical fashion was collected 96 hours post RT.
TRX1 expression was determined via western blot. *P≤0.0001.
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Figure 11. CONP-induced JNK activation results in apoptosis in pancreatic
tumors.
Tumor tissues were collected at the time when mice were sacrificed. Formalin-fixed and
paraffin embedded, immediately adjacent tissue sections were used for staining. (A-D)
p-JNK staining (brown) and (E-H) cleaved caspase 3 staining (brown) show that RT or
CONPs alone both increased apoptotic signaling compared to un-treated mice, while
the combination of CONPs and RT (D, H) dramatically increased JNK activation and the
corresponding apoptotic signaling when compared to any other group.
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Figure 12. CONPs are unable to drive RT-induced apoptosis in the absence of
JNK function.
L3.6pl or Panc1 pancreatic cancer cells were treated with 20 µM specific JNK inhibitor
(SP600125) with or without 10 µM CONPs for 24 hours prior to RT. Caspase 3/7
activation and cell viability were determined 24-96 hours post RT. Caspase 3/7
activation was completely mitigated in response to treatment in (A) L3.6pl cells and
dramatically reduced in (B) Panc1 cells. Sensitization was no longer observed in (C)
L3.6pl or (D) Panc1 cells following JNK inhibition. *P≤0.005 compared to control.
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Figure 13. CONPs are unable to drive sensitization in the absence of TRX1
oxidation.
Cell lines expressing wild type TRX1, C32S TRX1, C35S TRX1, or empty pLVPZ vector
were treated with 10 μM CONPs for 24 hrs followed by 5 Gy RT. Caspase 3/7 activation
and cell viability were determined 24-96 hours post RT. Caspase 3/7 activation was
completely mitigated in response to treatment in (A) L3.6pl cells and dramatically
reduced in (B) Panc1 cells. Radiosensitization (as determined by reduced viability) was
no longer observed in (C) L3.6pl or (D) Panc1 cells pre-treated with CONPs following
TRX mutation. *P≤0.05 compared to RT alone. TRX1 expression is shown in Fig. S10.
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CHAPTER 5: CERIUM OXIDE NANOPARTICLES DOWNREGULATE
ANGIOGENESIS IN PANCREATIC TUMORS
Introduction
Cancer cells are characterized by uncontrolled cell growth and division, resulting
in tumor formation in solid human malignancies, such as pancreatic cancer. Both
hematologic and solid cancers require the growth of new blood vessels, known as
angiogenesis (78). Specifically, tumor angiogenesis includes the development of new
irregular blood vessels from the established vascular network (66). Whereas the actual
cancer cells were historically the targets of therapies, the last ten years has seen the
addition of agents designed to target the vasculature required to support tumor growth
(78).
Tumor blood vessel formation facilitates disease progression in many ways,
including the deposition of oxygen and nutrients, as well as the removal of catabolites
and carbon dioxide (78). Additionally, endothelial cells have been shown to produce
growth and anti-apoptotic factors which they supply to tumors; one endothelial cell can
control the growth of up to 100 tumor cells (78). Finally, angiogenesis enables tumor
cells to penetrate vessel walls and be transported to distant metastatic sites in the body
(2). The array of processes affected by angiogenesis makes it an interesting and
important factor to consider, especially in the context of a radical modulating agent such
as CONPs.
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Vascular endothelial growth factor (VEGF) is one of the key drivers of
angiogenesis in cancer (2). Though many types of cancer cells constitutively
overexpress VEGF without any stimuli, hypoxia (low oxygen) and acidosis (low
extracellular pH) are two conditions commonly found in expanding tumors that have
been shown to drive angiogenesis by up regulating the expression of VEGF (3).
Radiation therapy has also been shown to up regulate VEGF expression, by decreasing
the available oxygen in the cell (6). It is thought to be through the up regulation of VEGF
that many of the negative effects of radiation are mediated in the cells which survive
radiation treatment, including increased aggressiveness, proliferation, migration,
invasion, and angiogenic ability (6). Therefore, a radiation adjuvant that mitigated the
RT-induced VEGF expression could have both immediate and long term effects on
patients.
As angiogenesis plays an important role in tumor growth, progression,
metastasis, and response to radiotherapy, therapies that modulate oxygen availability in
cancer cells must consider the impact on angiogenesis. CONPs are one such
compound that has been shown to modulate ROS levels in pancreatic cancer cells,
especially in response to RT (19), which suggests that they may also impact
angiogenesis in pancreatic tumors as ROS have recently been shown to regulate
angiogenesis through the regulation of VEGF expression (66). Treatment with CONPs
has been shown to inhibit angiogenesis in ovarian cancer, as observed by decreased
CD31 staining (66). Despite the evidence suggesting therapeutic potential, this is the
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first study to determine the role of CONPs in regulating angiogenesis in pancreatic
tumors.
Methods and Materials
Antibodies and Reagents
Purified rat anti-mouse CD31 antibody (550274) was purchased from BD
Pharmingen (San Jose, CA). VECTASTAIN Elite ABC system (pk-7200) and DAB
Peroxidase Substrate Kit (SK-4100) were purchased from Vector Laboratories
(Burlingame, CA).
Orthotopic Injection of Pancreatic Cancer Cells in Athymic Nude Mice
Female athymic nude mice (NCI-nu) were purchased from the Animal Production
Area of the National Cancer Institute Frederick Cancer Research and Development
Center. The mice were housed and maintained in specific pathogen-free conditions in
facilities approved by the American Association for Accreditation of Laboratory Animal
Care and in accordance with current regulations and standards of the United States
Department of Agriculture, United States Department of Health and Human Services,
and the National Institute of Health. The mice of 8 to 12 weeks of age were used in
accordance under institutional guidelines with approved IACUC protocol. Human care of
the mice was thoroughly considered. To develop tumors, L3.6pl cells were harvested
from culture dishes and injected as previously described (56-58).
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Therapy of Established Human Pancreatic Carcinoma Tumors Grown In the Pancreas
of Nude Mice
Immediately following injection of cancer cells (1 x 10 6) into the pancreas, the
mice were randomized into two groups (n = 20) as follows: (a) twice weekly
intraperitoneal (i.p.) injections of saline in control groups; (b) twice weekly (Tuesday and
Thursday) i.p injections of CONPs (15 µM; 0.01 mg/kg). Two weeks later each group
was randomized into 2 sub-groups (n = 10) as follows: (c) continued with twice weekly
i.p injections of saline (for control group) or twice weekly i.p. injections of CONPs; (d)
twice weekly i.p. injections of saline or CONPs and thrice-weekly administration of 5 Gy
radiation for 2 weeks (30 Gy total). All treatment groups continued to receive twice
weekly i.p. injections of saline (control) or CONPs for 2 additional weeks (for a total of 6
week treatment). Mice were sacrificed at 8 weeks (day 56) and subjected to necropsy.
Primary tumors in the pancreas were excised and weighed. Tumor volumes were
determined by liquid displacement analysis.
Staining for Angiogenesis
Slides were baked overnight at 57oC, followed by deparaffinization and
rehydration via subsequent washes (twice each) with xylene, 100% ethanol, 95%
ethanol, and dH2O. Citrate buffer (10 µM) at pH 6 brought to sub boiling temperature for
10 minutes was used as an antigen unmasking agent. Slides were subsequently
washed in dH20 and incubated in 3% H2O2 for 10 minutes to block endogenous
peroxidase. Following additional washing in dH2O, sections were blocked with a
blocking solution containing horse serum at room temperature for 20 minutes. Sections
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were then incubated in primary antibody against mouse CD-31 at a dilution of 1:100 at
room temperature for 30 minutes. After washing with PBST, biotinylated “universal”
secondary antibody was added and incubated for 30 minutes at room temperature.
Slides were then washed with PBST before being incubated 30 minutes at room
temperature with R.T.U. ABC reagent. Additional washes with PBST were then
performed, followed by addition of DAB reagent to each slide for 8 minutes and then
submersion in dH2O.

Slides were

counterstained

with

hematoxylin

per the

manufacturer’s instructions. After subsequent washes, slides were dehydrated by
incubation in 95% ethanol, 100% ethanol, and xylene. Sections were mounted using
Permount Mounting Media (Fisher).
Results
Combination Therapy With CONPs and RT Decreases Angiogenesis in Pancreatic
Tumors
Tumors from mice receiving each treatment all displayed angiogenesis as
indicated by the positive brown CD-31 staining (Figure 14). (A-B) Tumors from control
mice (saline injected) showed the greatest level of angiogenesis, followed by (C-D) mice
that underwent only radiation therapy. (E-F) mice receiving CONPs only showed a
similar amount of staining to RT treated mice, but at a lower intensity. (G-H) Mice that
received CONPs in combination with RT showed the lowest level of angiogenesis of any
group, with very few CD-31 positive areas visible.
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Discussion
The degree of pancreatic tumor vascularization has been inversely linked to
patient outcomes, with hyper-vascularization associated with decreased survival (2).
Conversely, tumor hypo-vascularization has been linked to extended survival in patients
and researchers have shown that inhibition of pancreatic cancer angiogenesis in vivo
suppresses tumor growth (2). Further, the response of the tumor vasculature is a critical
determinant in the success of radiation therapy (6). In exposed endothelial cells, RT can
activate pro-survival pathways to support tumor vascularization, contributing to the
failure of radiation therapy by increasing angiogenesis within tumors (6). It would appear
that treatment with CONPs down regulates angiogenesis that would be present in the
absence of CONPs. However, based on the current data, it is unclear whether RT is
effectively killing more cells, thereby inhibiting angiogenesis, or if CONP inhibited
angiogenesis is enabling RT to kill more cells. Likely, the reality is a mix of the two
situations. Nevertheless, this study suggests that CONPs impact both cancer cells as
well as tumor microenvironment to sensitize cancer cells to RT. It would be both
interesting and important to determine if CONPs inhibited angiogenesis through the
down regulation of VEGF, as suggested and shown in the ovarian model (66).
Of note, the study that determined CONPs inhibited angiogenesis in an ovarian
cancer mouse model also noted that CONPs were able to inhibit metastasis of ovarian
cancer cells (66). As it has been shown that the up regulation of VEGF increases the
metastatic ability of cancer cells, it is suggested that the inhibition of angiogenesis by
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CONPs is the driver behind the reduction of metastasis in the ovarian model (66).
Despite the fact that L3.6pl is a highly metastatic cell line derived from liver metastasis,
none of the mice in the control group of this study developed metastasis detectable by
visual inspection at the time of termination. Therefore, we were unable to determine if
CONPs reduced the metastatic potential of pancreatic tumor cells in the current study.
However, more sophisticated analysis of the liver following an experiment with an
extended duration may address this issue. Further, performing an experiment where
L3.6pl cancer cells were injected through the tail vain of mice treated with CONPs would
be an interesting study to address the impact of CONPs on angiogenesis and the
subsequent metastasis based on the resulting metastasis to the liver, among other
potential locations.
Conclusion
Currently, these results are only preliminary. However, the results appear very
positive. CONPs displayed the clear ability to down regulate angiogenesis and,
excitingly, an enhanced ability to down regulate angiogenesis in the presence of
radiation. The results are in line with both the suggested outcome in pancreatic cancer
and the outcomes demonstrated in ovarian cancer. Overall, the ability of CONPs to
decrease angiogenesis in pancreatic tumors shows promise and should be further
pursued as a potential mechanism of radiosensitization for pancreatic cancers.
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Figure 14. CONP treatment decreases blood vessel formation in pancreatic
tumors.
Tumor sections collected at the time of termination were stained with CD-31 as a
marker for angiogenesis. Representative images are shown at 10x and 40x. Control,
RT, and CONP treated groups all had comparable levels of angiogenesis. Co-treated
tumors (G,H) showed significantly lower levels of angiogenesis compared to all other
groups.
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CHAPTER 6: CONCLUSION
Impact
This is the first report on the usage of cerium oxide nanoparticles to treat
pancreatic cancer. CONPs demonstrated selective toxicity to human pancreatic cancer
cells without inducing toxicity in the corresponding normal human pancreatic epithelial
cells. Though it was suggested by several groups, this is also the first report to
demonstrate the ability of CONPs to sensitize cancer cells to RT. By ruling out mitotic
catastrophe and then systematically analyzing ROS production and apoptotic signaling,
this work provided a specific, novel mechanism by which the sensitization of pancreatic
cancer cells by CONPs occurs.
Many of the mechanisms and pathways discussed here in the context of
pancreatic cancer are, by no means, unique to that specific disease site. Certain
factors, like uptake, do need to be confirmed for each cell type, but some do not. For
instance, most cancer cells are thought to exist at an acidic pH that would favor H2O2
production by CONPs through SOD activity; most normal cells are thought to exist at a
neutral pH which would favor radical scavenging by CONPs. Solid tumors found in
many different disease sites are widely accepted to experience hypoxia, acidosis, and
angiogenesis. With CONP toxicity to several types of cancer already established, it
would be interesting to investigate the ability of CONPs to sensitize other types of
cancer to radiation treatment.
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The interactions of CONPs in cells are still being elucidated. As such, we cannot
rule out pathways or interactions not specifically addressed in this work. Apoptosis is a
carefully regulated process in normal cells and becomes even more tightly controlled in
cancer cells as they attempt to evade death. With the numerous regulatory proteins and
feedback loops, the regulation of other apoptotic pathways through ROS production,
direct oxidation by CONPs, or other unidentified mechanisms are real possibilities which
still need to be considered in pancreatic cancer and other forms of the disease.
Moving Forward
Pancreatic Cancer
Despite advances in the diagnosis and treatment of many cancers, pancreatic
cancer patients still face a bleak outlook upon diagnosis. The rapid progression of the
disease commonly results in late stage diagnosis and the need to treat patients with
advanced and unrespectable tumors. Unfortunately, current treatment options are either
completely ineffective or unable to improve patient outcomes long term. Improvements
in the therapies currently available and identification of novel therapeutic strategies
remains an important task, especially in pancreatic cancer. The establishment of more
effective treatments could have a dramatic impact on the amount of time patients
survive after being diagnosed with pancreatic cancer. The use of CONPs as a therapy
or an adjuvant therapy for pancreatic cancer shows potential in making that happen.
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Cerium Oxide Nanoparticle Therapies
Despite some conflicting in vitro data regarding toxicity, in vivo data about the
toxicity and application of CONPs for the treatment cancer are positive thus far. In
contrast with currently available ROS modulators, which are characterized by a short
half-life, necessitate extensive dosing, and usually require the introduction of one
molecule for each radical to be modified, CONPs persist in the body with a single
particle scavenging or generating many free radicals or inducing the oxidation of several
targets through the auto-regenerative capacity of CONPs. As a compound that is
selectively toxic to cancer cells and selectively sensitizes cancer cells to established
therapies, without harming normal cells or, in some cases, actually protecting normal
cells, the therapeutic potential for CONPs appears to be vast.
However, for CONP-based therapies to gain acceptance and approval, some
questions must still be addressed. We need a better understanding of where CONPs go
when introduced into a cell or biological system. Current dosing regiments may be wildly
excessive or may be considerably below the level optimum for CONP-induced
protection or sensitization. Determining what percentage of CONPs make their way to a
tumor or at what concentration tumors become saturated would certainly shed light on
the ideal dosing regiments. Understanding the nanokinetics and nanodynamics of
CONPs would also facilitate better implementation of CONP-based therapies.
Finally, increased standardization and categorization of CONPs is essential.
There is extensive diversity in particles synthesized by various individual group or
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commercial players, from size to shape to 3+/4+ ratio, yet all are referred to as “cerium
oxide nanoparticles.” Each of those characteristics can have a dramatic effect on the
toxicity and activity associated with the specific particle. Therefore, for therapy to
become standardized, the particles themselves must also become standardized. If the
particles can be standardized and dosing can be optimized, CONPs have real potential
as a therapeutic agent for the treatment of cancer.
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300 µM

Supplemental Figure 1. CONPs have a concentration and time dependent impact
on H2O2 production.
Supplemental to Fig. 2 showing all the CONP concentrations and time points examined.
CONPs were included in water 0.5 h prior to RT (A & B), 1 h post-RT or 24 hr post-RT.
Time in hours, time point post-RT.
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CONP Concentration [µM]

Supplemental Figure 2. RT-induced H2O2 production is quantifiable and
comparable in water or PBS.
H2O2 production by CONPs in PBS at neutral pH (7.4) is comparable to that of CONPs
suspended in water. When CONPs were added to PBS prior to RT, there was not a
discernible difference between H2O2 production by CONPs suspended in water and
CONPs suspended in PBS.
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Supplemental Figure 3. CONPs do not introduce artifact into the Amplex Red
readings.
Supplemental to Figure 2 & 3 showing CONP presence does not disturb the recording
of H2O2 value by Amplex Red assay. CONPs were either left in the reaction (Present) or
removed by centrifugation (Removed) prior to fluorescent analysis of H2O2.
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A

B

C

Supplemental Figure 4. L3.6pl cancer cells are mare acidic than normal hTERTHPNE cells.
Supplemental to Fig. 4 showing that L3.6pl pancreatic cancer cells (A) are more acidic
than hTERT-HPNE normal pancreatic epithelial cells (B). The acidity inside the cells
was determined as described in Methods and presented as mean fluorescent intensity.
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Supplemental Figure 5. Acidic conditions inhibit CONP radical scavenging.
Supplemental to Fig. 3 showing that under acidic conditions, CONPs lose the ability to
scavenge radicals, but not enhance radical production. Graphs show the extended
analysis of H2O2 production by various CONP concentrations at varying time points
beyond what is described in figure 3. A. CONPs were added to acidic PBS (pH 3) 24
hours prior to 3 or 5 Gy RT. B. CONPs were added to acidic PBS (pH 5) 24 hours prior
to 3 or 5 Gy RT.
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Supplemental Figure 6. CONPs do not alter AKT, ERK 1/2, or p53 signaling in
pancreatic cancer cells.
Supplemental to Figure 8. L3.6pl pancreatic cancer cells were treated with 0 or 10 µM
CONPs followed by exposure to 0 or 5 Gy RT 24 hours later. Cell lysate was collected
and analyzed via ELISA 72 hours later for (A) p-AKT, (B) p-ERK 1/2, or (C) p-p53.
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Supplemental Figure 7. Bright field imaging of p-ASK1 stained slides.
Supplemental to Figure 10. The slides imaged with fluorescent microscopy to determine
ASK1 phosphorylation were also imaged with bright field microscopy to confirm that
slides contained comparable numbers of slides at the time of imaging.
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Supplemental Figure 8. CONPs are unable to drive sensitization in the absence of
JNK function.
Supplemental to Figure 12. Cells were treated with 20 µM JNK inhibitor (BI 78D3) with
or without 10 µM CONPs 24 hours prior to RT. Caspase 3/7 activation and cell viability
were determined 24-96 hours post RT. Caspase 3/7 activation was mitigated in
response to treatment in (A) L3.6pl cells and dramatically reduced in (B) Panc1 cells.
Sensitization was no longer observed in (C) L3.6pl or (D) Panc1 cells following JNK
inhibition. *P≤0.005 compared to untreated.
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Supplemental Figure 9. CONPs are unable to drive radiosensitization in the
absence of JNK expression.
Supplemental to Figure 12. Cells were transfected with JNK specific or control siRNA
followed 24 hours later by 0 or 10 µM CONPs followed by RT 24 hours later. (A) siRNA
knockdown of JNK in L3.6pl and Panc1 cells was determined via western blot 96 hours
post RT. (B) Caspase 3/7 activation and (C) sensitization were no longer observed in
Panc1 cells after JNK kd. *P≤0.005 compared to Ctrl. +P≤0.05 compared to RT.
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Supplemental Figure 10. Infected cell lines express wild type or mutant TRX1.
Supplemental to Figure 13. L3.6pl and Panc1 cells were infected with HA tagged wild
type TRX1, C32S mutant TRX1, C35S mutant TRX1, or the empty pLVPZ vector.
Western blot for HA shows expression only in the cell lines expressing wild type or
mutant TRX1-HA.
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Protocol Figure 2 A-B
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Protocol Figure 3 A-B
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Animal Dosing Schematic Figure 6, 11, 14 and Table 1
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Dissertation Title: “Cerium Oxide Nanoparticles Sensitize Pancreatic Cancer Cells to
Radiation by Promoting Acidic pH, ROS and JNK Dependent Apoptosis”
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ABSTRACT
Side effects of radiation therapy (RT) remain the most challenging issue for
pancreatic cancer treatment. In this report we determined whether and how cerium
oxide nanoparticles (CONPs) sensitize pancreatic cancer cells to RT. CONP
pretreatment enhanced radiation-induced reactive oxygen species (ROS) production
preferentially in acidic cell-free solutions as well as acidic human pancreatic cancer
cells. In acidic environments, CONPs favor the scavenging of superoxide radical over
the hydroxyl peroxide resulting in accumulation of the latter whereas in neutral pH
CONPs scavenge both. CONP treatment prior to RT markedly potentiated the cancer
cell apoptosis both in culture and in tumors and the inhibition of the pancreatic tumor
growth without harming the normal tissues or host mice.
Mechanistically, CONPs were not able to significantly impact RT-induced DNA
damage in cancer cells, thereby ruling out sensitization through increased mitotic
catastrophe. However, JNK activation, which is known to be a key driver of RT-induced
apoptosis, was significantly upregulated by co-treatment with CONPs and RT in
pancreatic cancer cells in vitro and human pancreatic tumors in nude mice in vivo
compared to CONPs or RT treatment alone. Further, CONP-driven increase in RTinduced c-Jun terminal kinase (JNK) activation was associated with marked increases in
Caspase 3/7 activation, indicative of apoptosis. We have shown CONPs increase ROS
production in cancer cells; ROS has been shown to drive the oxidation of thioredoxin
(TRX) 1 which results in the activation of Apoptosis Signaling Kinase (ASK) 1. The
dramatic increase in ASK1 activation following the co-treatment of pancreatic cancer
cells with CONPs followed by RT in vitro suggests that increased JNK activation is the
result of increased TRX1 oxidation. The ability of CONPs to sensitize pancreatic cancer
cells to RT was mitigated when the TRX1 oxidation was prevented by mutagenesis of a
cysteine residue, or the JNK activation was blocked by an inhibitor,. Additionally,
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angiogenesis in pancreatic tumors treated with CONPs and RT was significantly
reduced compared to other treatment options.
In summary, these data demonstrate an important role and mechanisms for
CONPs in specifically killing cancer cells and provide novel insight into the utilization of
CONPs as a radiosensitizer and therapeutic agent for pancreatic cancer.
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